
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">



<head id="Head1"><meta name="google-site-verification" content="_VGwTV0Z3wNC7pQw33rX86U_BGdiQMqGvEu9XPCrV54" />
                
    <!--MOBIFY - DO NOT ALTER - PASTE IMMEDIATELY AFTER OPENING HEAD TAG -->
    <style type="text/css">
        .bannerTopo {
            width: 100%;
            height: auto;
            float: left;

        }
        .colorbox_login {
        }
    </style>
    
    <script type="text/javascript">
        /*<![CDATA[*/
        (function (n, p) {
            function d(a) {
                if (a.mode) {
                    var b = c("mobify-mode");
                    b && a[b] || (b = a.mode(l.ua));
                    return a[b]
                }
                return a
            }

            function g() {
                function a(b) {
                    n.addEventListener(b, function () {
                        l[b] = +new Date
                    }, !1)
                }
                n.addEventListener && (a("DOMContentLoaded"), a("load"))
            }

            function h() {
                var a = new Date;
                a.setTime(a.getTime() + 300000);
                p.cookie = "mobify-path=; expires=" + a.toGMTString() + "; path=/";
                n.location.reload()
            }

            function k() {
                e({
                    src: "https://preview.mobify.com/v7/"
                })
            }

            function c(a) {
                if (a = p.cookie.match(RegExp("(^|; )" + a + "((=([^;]*))|(; |$))"))) {
                    return a[4] || ""
                }
            }

            function f(a) {
                p.write('<plaintext style="display:none">');
                setTimeout(function () {
                    m.capturing = !0;
                    a()
                }, 0)
            }

            function e(j, o) {
                var i = p.getElementsByTagName("script")[0],
                    a = p.createElement("script"),
                    b;
                for (b in j) {
                    a[b] = j[b]
                }
                o && a.setAttribute("class", o);
                i.parentNode.insertBefore(a, i)
            }
            var m = n.Mobify = {},
                l = m.Tag = {};
            m.points = [+new Date];
            m.tagVersion = [7, 0];
            l.ua = n.navigator.userAgent;
            l.getOptions = d;
            l.init = function (b) {
                l.options = b;
                if ("" !== c("mobify-path")) {
                    if (g(), b.skipPreview || "true" != c("mobify-path") && !/mobify-path=true/.test(n.location.hash)) {
                        var i = d(b);
                        if (i) {
                            var a = function () {
                                i.post && i.post()
                            };
                            b = function () {
                                i.pre && i.pre();
                                e({
                                    id: "mobify-js",
                                    src: i.url,
                                    onerror: h,
                                    onload: a
                                }, "mobify")
                            };
                            !1 === i.capture ? b() : f(b)
                        }
                    } else {
                        f(k)
                    }
                }
            }
        })(window, document);
        (function () {
            var b = "//cdn.mobify.com/sites/onofre-mobile/production/adaptive.min.js";
            Mobify.Tag.init({
                mode: function (a) {
                    return /^((?!windows\sphone).)*(ip(hone|od)|android.*(mobile)(?!.*firefox))/i.test(a) ? "enabled" : "desktop"
                },
                enabled: {
                    url: b
                },
                desktop: {
                    capture: !1,
                    url: "//a.mobify.com/onofre-mobile/a.js"
                }
            })
        })(); /*]]>*/
    </script>
    <!-- END MOBIFY -->
    <script language="javascript" type="text/javascript">window.chaordic_meta = { "page": { "name": "product", "timestamp": new Date(),"selected_specs": {"sales_channel": "24"},"categories": [{"name": "Medicamentos","id": "55"},{"name": "Órgãos Sensoriais","id": "56","parents": ["55"]}]},"product": {"id": "8543","name": "Combigan Colírio Com 5ml","url": "/combigan-colirio-com-5ml/8543/05","description": "Tartarato de Brimonidipina+Timolol","images": {"300x300": "https://www.onofre.com.br/img/Busca/imagem_prescricao.jpg"},"categories": [{"name": "Medicamentos","id": "55"},{"name": "Órgãos Sensoriais","id": "56","parents": ["55"]}],"installment": {"count": 1,"price":79.44},"extra_info": {"otc": "yes"},"details": {"rating": {"total": "0","value": "0",},"codigo_interno": "206180","registro_ms": "1014701620019","volume": "0","quantidade": "100","generico": "nao","consulta_genericos": "False","programa_beneficio": "False","marca": "Allergan","urlMarca": "/busca/0/0/0/0/25/0/0/08"},"old_price": 103.17,"price": 79.44,"ean_code": "7897316804926","brand": "Allergan","status": "available","skus": [{"sku": "206180","specs": {"sales_channel": "20"},"price": 77.08,"old_price": 98.91,"installment": {"count": 1,"price":77.08},"status": "unavailable"},{"sku": "206180","specs": {"sales_channel": "8"},"price": 65.94,"old_price": 87.92,"installment": {"count": 1,"price":65.94},"status": "unavailable"},{"sku": "206180","specs": {"sales_channel": "27"},"price": 75.08,"old_price": 100.11,"installment": {"count": 1,"price":75.08},"status": "unavailable"},{"sku": "206180","specs": {"sales_channel": "34"},"price": 75.08,"old_price": 100.11,"installment": {"count": 1,"price":75.08},"status": "unavailable"},{"sku": "206180","specs": {"sales_channel": "38"},"price": 75.08,"old_price": 100.11,"installment": {"count": 1,"price":75.08},"status": "unavailable"},{"sku": "206180","specs": {"sales_channel": "737"},"price": 77.08,"old_price": 100.11,"installment": {"count": 1,"price":77.08},"status": "unavailable"},{"sku": "206180","specs": {"sales_channel": "750"},"price": 77.08,"old_price": 100.11,"installment": {"count": 1,"price":77.08},"status": "unavailable"},{"sku": "206180","specs": {"sales_channel": "783"},"price": 77.08,"old_price": 98.91,"installment": {"count": 1,"price":77.08},"status": "unavailable"},{"sku": "206180","specs": {"sales_channel": "18"},"price": 79.44,"old_price": 105.76,"installment": {"count": 1,"price":79.44},"status": "available"},{"sku": "206180","specs": {"sales_channel": "12"},"price": 79.44,"old_price": 103.17,"installment": {"count": 1,"price":79.44},"status": "available"},{"sku": "206180","specs": {"sales_channel": "24"},"price": 79.44,"old_price": 103.17,"installment": {"count": 1,"price":79.44},"status": "available"},{"sku": "206180","specs": {"sales_channel": "144"},"price": 79.44,"old_price": 103.17,"installment": {"count": 1,"price":79.44},"status": "available"}],"specs": {"sales_channel": ["20","8","27","34","38","737","750","783","18","12","24","144"]}}}</script>
    <!--Script Chaordic Loader-->
    <script async defer src="//static.chaordicsystems.com/static/loader.js" data-apikey="onofrefarma"></script>
    <!--<script type="text/javascript"> var headID = document.getElementsByTagName("head")[0]; var newScript = document.createElement('script'); newScript.type = 'text/javascript'; newScript.src = '//static.chaordicsystems.com/static/loader.js'; newScript.setAttribute('data-apikey', 'onofrefarma'); newScript.async = true; newScript.defer = true; headID.appendChild(newScript); </script> -->
    <!--Script Chaordic Loader - FIM -->
    <meta name="viewport" content="width=device-width, initial-scale=1.0" /><meta http-equiv="X-UA-Compatible" content="IE=8" /><title>
	Combigan Colírio Com 5ml | Onofre 
</title>

    <script src="Jss/gaEventos.js"></script>
    <link type="image/x-icon" href="https://www.onofre.com.br/favicon.ico" rel="icon" /><link type="image/x-icon" href="https://www.onofre.com.br/favicon.ico" rel="SHORTCUT ICON" />
        <!-- CSS -->
        <link href="/Jss/Colorbox/colorbox.css" rel="stylesheet"/>
<link href="/Jss/ToolTip/bubbletip/bubbletip.css" rel="stylesheet"/>
<link href="/Jss/ToolTip/bubbletip/bubbletip-IE.css" rel="stylesheet"/>
<link href="/Css/resetNovo.css" rel="stylesheet"/>
<link href="/Css/star_rating.css" rel="stylesheet"/>
<link href="/Css/EstiloMasterNovo.css" rel="stylesheet"/>
<link href="/Css/MasterNova.css" rel="stylesheet"/>
<link href="/shadowbox/shadowbox.css" rel="stylesheet"/>
<link href="/Css/rodape.css" rel="stylesheet"/>
<link href="/Css/EstiloExtraBucks.css" rel="stylesheet"/>
<link href="/assets/css/base.css" rel="stylesheet"/>
<link href="/assets/css/common.css" rel="stylesheet"/>

        <link href="/Css/AutenticacaoPBM.css" rel="stylesheet" />
        <!-- CSS -->
        <!-- JSS -->
        <script src="/Jss/jquery_onofre.js"></script>
<script src="/Jss/jquery.maskMoney.js"></script>
<script src="/shadowbox/shadowbox.js"></script>
<script src="/Jss/jquery.cookie.js"></script>
<script src="/Jss/Colorbox/jquery.colorbox-min.js"></script>
<script src="/Jss/Dialog/jquery-ui-1.10.1.custom.min.js"></script>
<script src="/Jss/generic.js"></script>
<script src="/Jss/jqzoom.pack.1.0.1.js"></script>
<script src="/Jss/jquery.hoverIntent.minified.js"></script>
<script src="/Jss/ToolTip/jQuery.bubbletip-1.0.6.js"></script>
<script src="/Jss/ToolTip/ToolTip.js"></script>
<script src="/assets/js/lib/owl.carousel.min.js"></script>
<script src="/assets/js/main.js"></script>
<script src="/Jss/Utils/MasterPage.js"></script>

        <script src="/Jss/AutenticaFloatBar.js"></script>
        <link href="/Css/select2.min.css" rel="stylesheet" />
        <script src="/Jss/Utils/select2.min.js"></script>
        <link href="/Css/MasterResponsivo.css" rel="stylesheet" />
        <script src="/Jss/Utils/Home.js"></script>
        <script type="text/javascript" src='https://www.google.com/recaptcha/api.js'></script>
        <!-- JSS -->
    
    <!--[if lt IE 9]> <script src="https://html5shim.googlecode.com/svn/trunk/html5.js"></script> <![endif]-->
    <!-- JSS -->
    
    
    
    <script type='text/javascript' src='https://v2.afilio.com.br/mastertag.php?progid=1719&type=product&id_partner=drogariaonofre&product_id1=8543&id_category=0&stock=0&product_sku=&product_name=COMBIGAN COL 5ML&product_desc=Combigan Colírio Com 5ml&product_photo=https://www.onofre.com.br/estatico/Produto/Normal/&price1=79,44&price2=103,17&product_currency=BRL&url_product=http://www.onofre.com.br/DetalheProduto/Default.aspx?ProductName=combigan-colirio-com-5ml&ProductId=8543'></script>
    <link href="/Css/EstiloDetalheProduto.css" rel="stylesheet"/>
<link href="/Css/jqzoom.css" rel="stylesheet"/>
<link href="/Jss/Colorbox/colorbox.css" rel="stylesheet"/>
<link href="/assets/css/prateleira.css" rel="stylesheet"/>
<link href="/assets/css/produto.css" rel="stylesheet"/>
<script type="text/javascript" src="/Jss/DetalheProduto.js" defer></script>
<script type="text/javascript" src="/Jss/jqzoom.pack.1.0.1.js" defer></script>
<script type="text/javascript" src="/Jss/zoom/jquery.jqzoom-core.js" defer></script>
<script type="text/javascript" src="/jss/zoom/zoom.js" defer></script>
<script type="text/javascript" src="/Jss/Colorbox/jquery.colorbox-min.js" defer></script>
<script type="text/javascript" src="/Jss/Utils/DetalheProduto.js" defer></script>
<script type="text/javascript" src="/assets/js/produto.js" defer></script>

    <script type="text/javascript">        /*<![CDATA[*/ var dataLayer = [{
                               'site' : { 'domain' : document.location.host },
                               'page' : { 
                                            'name' : document.title,
                                            'pageType' : 'product'
                                        },
                                               'product' : {
                                               'productName' : 'COMBIGAN COL 5ML',
                                               'productId' : '8543',
                                               'productCategory' : '',
                                               'productSubCategory' : '',
                                               'productPrice' : '79.44',
                                               'productBrand' : 'Allergan'
                                           },
                               'session' : {
                                                'isLogged': false,
                                                'user' : { 'id' : 'VISIT-572854183' }
                                           }
                                }];; /*]]>*/ </script>
<link rel="stylesheet" type="text/css" href="//onofre.resultspage.com/autocomplete/sli-rac.css" /><meta name="description" content="Combigan Colírio Com 5ml da Allergan com o menor preço é na Onofre. Receba seu pedido em casa pagando em até 3x. Compre agora!" /></head>
            

<body id="body" class="produto">

    <!-- BANNER TOPO -->
    
    <div class="bannerTopo" style="max-height: 100px">
        
    </div>
    <!-- FIM - BANNER TOPO -->
    <script type="text/javascript" src="//onofre.resultspage.com/autocomplete/sli-rac.config.js"></script>
    
    <!-- Start Alexa Certify Javascript -->
    <script type="text/javascript" src="https://d31qbv1cthcecs.cloudfront.net/atrk.js"></script>
    <script type="text/javascript">
        _atrk_opts = {
            atrk_acct: "xfCse1aALO00g7",
            domain: "onofre.com.br"
        };
        atrk();
    </script>
    <noscript>
        <img src="https://d5nxst8fruw4z.cloudfront.net/atrk.gif?account=xfCse1aALO00g7" style="display: none" height="1" width="1" alt="" />
    </noscript>
    <script type="text/javascript">
        /* Set the width of the side navigation to 250px */
        function openNavMobile() {
            document.getElementById("mySidenav").style.width = "255px";
        } /* Set the width of the side navigation to 0 */
        function closeNavMobile() {
            document.getElementById("mySidenav").style.width = "0";
        }
    </script>
    <!-- End Alexa Certify Javascript -->
    <form method="post" action="/combigan-colirio-com-5ml/8543/05" id="form1">
<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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" />

<script> ECO_Step='Product';</script><script> ECO_DepName='';</script><script> ECO_DepId='';</script><script> ECO_CatName='';</script><script> ECO_CatId='';</script><script> ECO_ProdName='combigan-colirio-com-5ml';</script><script> ECO_ProdId='8543';</script><script> ECO_ProdValue='79.44';</script><script> ECO_ProdSumValue='79.44';</script><script> ECO_ProdQty='1';</script><script> ECO_ProdAvgValue='79,44';</script>
<script type="text/javascript">
//<![CDATA[
products = []; products.push( {'id':206180,'name':'Combigan Colírio Com 5ml','category':'Órgãos Sensoriais','price':79.44,'quantity':0,'brandId':25});var productData ={   'transaction': {'id':0,     'products': products}};//]]>
</script>

<script src="/ScriptResource.axd?d=BnWrJ6-gLV3GlI8g28LCzYXkfKJLttyoigz0AJpfnvO4NN21YTBbDD9JctBIuGGW8YufhqFw-AnVHbmyWvfFb_B2w9DMLRk3OO9iqYmkxfGcvnVf4ImxaGFLKlWYiwlxPddzmc-9JHkJ8clChxff5mADpJw1&amp;t=42a7acab" type="text/javascript"></script>
<input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="53BE6E71" />
<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAtp7Uo+9Q4C11Zrl3OL7lDrvGJREAXUqdHbn/uqryQegasCjseFQU1IG6a1QV/1IsPDvqD576IjU8b+VycT56M9ED22EwkGKj1YkpT+X+kXiM56f9BvruTcOsm75dsnP4j+rR3kChNt2jv+P1A6lf1Kfh0m/YFL+gqaOapTOLGCT3uEmapvkS7PnXX2p48aV5JXiYT1tmrUuDA14lwoxMmxwwFaVvdlxqKyIPzmKQOht1Yfk35WIc22z8VFS7Q07kBQnSjh" />
        
        <!-- Master -->
        
        <!-- Header -->
        <div id="mySidenav" class="sidenav">
            
            <a href="javascript:void(0)" id="divMobileLogin"><span style="float: left; font-size: 18px; text-decoration: underline" onclick="window.location.href='https://www.onofre.com.br/acesso/'">Faça o login ou cadastre-se</span>
                <br />
                <span class="closebtn" onclick="closeNavMobile()">&times;</span></a>
            <!--<a href="#">About</a> <a href="#">Services</a> <a href="#">Clients</a> <a href="#">Contact</a>-->
            <hr />
            <nav id="mobile-nav" class="page-nav">
                                    <div class="wrapper full">
                                        <ul class="nav-list">
                                            <li class="medicamentos-e-saude"><a onclick="$('.medicamentos-e-saude .sub-nav').toggle();" title="Medicamentos" class="nav-link">Medicamentos</a>
                                                <div class="sub-nav">
                                                    <ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Intestino e Digestão</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/saude-digestiva/44/03' class='medi-sub-nav-link' >Saúde Digestiva</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiflatulento/54/03' class='medi-sub-nav-link' >Antiflatulento</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiacido/95/03' class='medi-sub-nav-link' >Antiácido</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/laxante/248/03' class='medi-sub-nav-link' >Laxante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Diabetes</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipoglicemiante/234/03' class='medi-sub-nav-link' >Hipoglicemiante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Hormônios</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antigotoso/57/03' class='medi-sub-nav-link' >Antigotoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/tireoidiano/342/03' class='medi-sub-nav-link' >Tireoidiano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Infecções</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antibiotico/32/03' class='medi-sub-nav-link' >Antibiótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-infeccioso/67/03' class='medi-sub-nav-link' >Anti-infeccioso</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Aparelho Urinário</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidiuretico/46/03' class='medi-sub-nav-link' >Antidiurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antilitiasico/80/03' class='medi-sub-nav-link' >Antilitiásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/diuretico/190/03' class='medi-sub-nav-link' >Diurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/incontinencia-urinaria/242/03' class='medi-sub-nav-link' >Incontinência Urinária</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Nervoso</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivertiginoso/112/03' class='medi-sub-nav-link' >Antivertiginoso</a></li><li class='medi-sub-nav-item'><a href='/homeopaticos/calmante/147/03' class='medi-sub-nav-link' >Calmante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-tubo-neural/188/03' class='medi-sub-nav-link' >Distúrbio do Tubo Neural</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/neuropsicoestimulante/278/03' class='medi-sub-nav-link' >Neuropsicoestimulante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Gripe e Resfriado</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitussigenos/109/03' class='medi-sub-nav-link' >Antitussígenos</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante/179/03' class='medi-sub-nav-link' >Descongestionante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/irritacoes-da-garganta/246/03' class='medi-sub-nav-link' >Irritações da Garganta</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/expectorante-e-mucolitico/274/03' class='medi-sub-nav-link' >Expectorante e Mucolítico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Anti-Hipertensivo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiarritmico/27/03' class='medi-sub-nav-link' >Antiarritmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hipertensivo/62/03' class='medi-sub-nav-link' >Anti-hipertensivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/cardiotonico/149/03' class='medi-sub-nav-link' >Cardiotônico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipertensor/231/03' class='medi-sub-nav-link' >Hipertensor</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Cuidado com os Olhos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/orgaos-sensoriais/56/03' class='medi-sub-nav-link' >Órgãos Sensoriais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante-ocular/180/03' class='medi-sub-nav-link' >Descongestionante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/distrofia-do-globo-ocular/189/03' class='medi-sub-nav-link' >Distrofia do Globo Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/lubrificante-ocular/260/03' class='medi-sub-nav-link' >Lubrificante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Circulatório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antianemico/26/03' class='medi-sub-nav-link' >Antianêmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hemorragico/61/03' class='medi-sub-nav-link' >Anti-hemorrágico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivaricoso/111/03' class='medi-sub-nav-link' >Antivaricoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hemostatico/221/03' class='medi-sub-nav-link' >Hemostático</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vermes e Parasitas</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifungico/52/03' class='medi-sub-nav-link' >Antifúngico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antimalarico/81/03' class='medi-sub-nav-link' >Antimalárico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparasitario/90/03' class='medi-sub-nav-link' >Antiparasitário</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Dor e Febre</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/analgesico/8/03' class='medi-sub-nav-link' >Analgésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anestesico/13/03' class='medi-sub-nav-link' >Anestésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antienxaquecoso/48/03' class='medi-sub-nav-link' >Antienxaquecoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-inflamatorio/69/03' class='medi-sub-nav-link' >Anti-inflamatório</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Alergias</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialergico/21/03' class='medi-sub-nav-link' >Antialérgico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Respiratório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiasmatico/29/03' class='medi-sub-nav-link' >Antiasmático</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/broncodilatador/142/03' class='medi-sub-nav-link' >Broncodilatador</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Pele e Mucosa</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/cicatrizante/155/03' class='medi-sub-nav-link' >Cicatrizante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/despigmentante/182/03' class='medi-sub-nav-link' >Despigmentante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/aftas/215/03' class='medi-sub-nav-link' >Aftas</a></li><li class='medi-sub-nav-item'><a href='/tratamento-rosto/antiacne/399/03' class='medi-sub-nav-link' >Antiacne</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vitaminas e Suplementos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifadiga/53/03' class='medi-sub-nav-link' >Antifadiga</a></li><li class='medi-sub-nav-item'><a href='/nutricosmeticos/antioxidante/88/03' class='medi-sub-nav-link' >Antioxidante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/orexigeno/281/03' class='medi-sub-nav-link' >Orexígeno</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/vitaminico/367/03' class='medi-sub-nav-link' >Vitamínico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Masculina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialopecia/20/03' class='medi-sub-nav-link' >Antialopécia</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiandrogenico/24/03' class='medi-sub-nav-link' >Antiandrogénico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disfuncao-eretil/185/03' class='medi-sub-nav-link' >Disfunção Erétil</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hiperplasia-prostatica-benigna/230/03' class='medi-sub-nav-link' >Hiperplasia Prostática Benigna</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Feminina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/anticoncepcionais/39/03' class='medi-sub-nav-link' >Anticoncepcionais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-ciclo-menstrual/187/03' class='medi-sub-nav-link' >Distúrbio do Ciclo Menstrual</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/indutor-da-ovulacao/243/03' class='medi-sub-nav-link' >Indutor da Ovulação</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/terapeutica-da-menopausa/337/03' class='medi-sub-nav-link' >Terapêutica da Menopausa</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Ósseo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiartrosico/28/03' class='medi-sub-nav-link' >Antiartrósico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiosteoporotico/87/03' class='medi-sub-nav-link' >Antiosteoporótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/osteoporose/94/03' class='medi-sub-nav-link' >Osteoporose</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/repositor-de-potassio/315/03' class='medi-sub-nav-link' >Repositor de Potássio</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Controle Especial</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidepressivo/42/03' class='medi-sub-nav-link' >Antidepressivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparkinsoniano/91/03' class='medi-sub-nav-link' >Antiparkinsoniano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Outros</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antineoplasico/84/03' class='medi-sub-nav-link' >Antineoplásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitabagismo/103/03' class='medi-sub-nav-link' >Antitabagismo</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul>
                                                         </div>
                                            </li>
                                            <li class="medicamentos-e-saude_new"><a onclick="$('.medicamentos-e-saude_new .sub-nav').toggle();" title="Saúde" class="nav-link">Saúde</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class='sub-nav-item'><a href='/geriatria/46/01' class='sub-nav-link' title='Geriatria'>Geriatria</a></li><li class='sub-nav-item'><a href='/higiene-e-limpeza/48/01' class='sub-nav-link' title='Higiene e Limpeza'>Higiene e Limpeza</a></li><li class='sub-nav-item'><a href='/homeopaticos/50/01' class='sub-nav-link' title='Homeopáticos'>Homeopáticos</a></li><li class='sub-nav-item'><a href='/alimentos-e-bebidas/52/01' class='sub-nav-link' title='Alimentos e Bebidas'>Alimentos e Bebidas</a></li><li class='sub-nav-item'><a href='/medicamentos/55/01' class='sub-nav-link' title='Medicamentos'>Medicamentos</a></li><li class='sub-nav-item'><a href='/cuidado-com-os-olhos/57/01' class='sub-nav-link' title='Cuidado com os Olhos'>Cuidado com os Olhos</a></li><li class='sub-nav-item'><a href='/ortopedia-e-acessorios/58/01' class='sub-nav-link' title='Ortopedia e Acessórios'>Ortopedia e Acessórios</a></li><li class='sub-nav-item'><a href='/primeiros-socorros/60/01' class='sub-nav-link' title='Primeiros Socorros'>Primeiros Socorros</a></li><li class='sub-nav-item'><a href='/sexo-seguro/61/01' class='sub-nav-link' title='Sexo Seguro'>Sexo Seguro</a></li><li class='sub-nav-item'><a href='/fitness-e-dietas/62/01' class='sub-nav-link' title='Fitness e Dietas'>Fitness e Dietas</a></li><li class='sub-nav-item'><a href='/testes-e-aparelhos/63/01' class='sub-nav-link' title='Testes e Aparelhos'>Testes e Aparelhos</a></li><li class='sub-nav-item'><a href='/vitaminas-e-naturais/65/01' class='sub-nav-link' title='Vitaminas e Naturais'>Vitaminas e Naturais</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A2"> <img id="Img2" /></a>
                                                        > </div>
                                                </div>
                                            </li>
                                            <li class="beleza-e-bem-estar"><a onclick="$('.beleza-e-bem-estar .sub-nav').toggle();" title="Beleza e Bem Estar" class="nav-link">Beleza e Bem Estar</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class='sub-nav-item'><a href='/tratamento-rosto/39/01' class='sub-nav-link' title='Tratamento Rosto'>Tratamento Rosto</a></li><li class='sub-nav-item'><a href='/cabelos/40/01' class='sub-nav-link' title='Cabelos'>Cabelos</a></li><li class='sub-nav-item'><a href='/corpo-e-banho/42/01' class='sub-nav-link' title='Corpo e Banho'>Corpo e Banho</a></li><li class='sub-nav-item'><a href='/cuidados-femininos/44/01' class='sub-nav-link' title='Cuidados Femininos'>Cuidados Femininos</a></li><li class='sub-nav-item'><a href='/cuidados-masculinos/49/01' class='sub-nav-link' title='Cuidados Masculinos'>Cuidados Masculinos</a></li><li class='sub-nav-item'><a href='/maos-e-pes/53/01' class='sub-nav-link' title='Mãos e Pés'>Mãos e Pés</a></li><li class='sub-nav-item'><a href='/maquiagem/54/01' class='sub-nav-link' title='Maquiagem'>Maquiagem</a></li><li class='sub-nav-item'><a href='/nutricosmeticos/56/01' class='sub-nav-link' title='Nutricosméticos'>Nutricosméticos</a></li><li class='sub-nav-item'><a href='/colonias/59/01' class='sub-nav-link' title='Colônias'>Colônias</a></li><li class='sub-nav-item'><a href='/tratamento-do-corpo/64/01' class='sub-nav-link' title='Tratamento do Corpo'>Tratamento do Corpo</a></li><li class='sub-nav-item'><a href='/higiene-bucal/68/01' class='sub-nav-link' title='Higiene Bucal'>Higiene Bucal</a></li><li class='sub-nav-item'><a href='/protecao-solar/69/01' class='sub-nav-link' title='Proteção Solar'>Proteção Solar</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A3"> <img id="Img3" /></a>
                                                         </div>
                                                </div>
                                            </li>
                                            <li class="mamae-e-bebe"><a onclick="$('.mamae-e-bebe .sub-nav').toggle();" title="Mamãe e Bebê" class="nav-link">Mamãe e Bebê</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class='sub-nav-item'><a href='/acessorios-infantis/37/01' class='sub-nav-link' title='Acessórios Infantis'>Acessórios Infantis</a></li><li class='sub-nav-item'><a href='/alimentos-infantis/38/01' class='sub-nav-link' title='Alimentos Infantis'>Alimentos Infantis</a></li><li class='sub-nav-item'><a href='/corpo-e-banho-infantil/41/01' class='sub-nav-link' title='Corpo e Banho Infantil'>Corpo e Banho Infantil</a></li><li class='sub-nav-item'><a href='/cuidados-com-a-mamae/43/01' class='sub-nav-link' title='Cuidados com a Mamãe'>Cuidados com a Mamãe</a></li><li class='sub-nav-item'><a href='/troca-de-fraldas/45/01' class='sub-nav-link' title='Troca de Fraldas'>Troca de Fraldas</a></li><li class='sub-nav-item'><a href='/cuidado-bucal-infantil/47/01' class='sub-nav-link' title='Cuidado Bucal Infantil'>Cuidado Bucal Infantil</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A4"> <img id="Img4" /></a>
                                                         </div>
                                                </div>
                                            </li>
                                            <li class="ofertas-e-lancamentos"><a onclick="$('.ofertas-e-lancamentos .sub-nav').toggle();" title="Ofertas e Lançamentos" class="nav-link"> Ofertas e Lançamentos</a>
                                                <div class="sub-nav">
                                                    <ul class="sub-nav-col">
                                                        <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/oferta/66" class="sub-nav-link" title="Ofertas">Ofertas</a></li>
                                                    </ul>
                                                    <ul class="sub-nav-col">
                                                        <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/lancamento/66" class="sub-nav-link" title="Lançamentos">Lançamentos</a></li>
                                                    </ul>
                                                    <div class="banner-menu">
                                                        <a id="A5"> <img id="Img5" /></a>
                                                         </div>
                                                </div>
                                            </li>
                                            <li class="como-comprar"><a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=251" title="Como Comprar" class="nav-link">Como Comprar</a> </li>
                                        </ul>
                                    </div>
                                </nav>
        </div>
        <header id="main-header" class="page-header">
                                <!--<div class="topbar-responsive"> <div class="wrapper-responsive full"> <div class="televendas col"> <p><span>Televendas:</span> <strong>4007-2526</strong></p> </div> <div class="social-responsive"> <ul class="social-list"> <li class="social-item"><a href="https://www.facebook.com/DrogariaOnofreOficial" class="social-link facebook" target="_blank" title="Facebook">Facebook</a></li> <li class="social-item"><a href="https://blogonofre.wordpress.com/" class="social-link beonofre" target="_blank" title="BeOnofre">BeOnofre</a></li>  </ul> </div> </div> </div>-->
                                <div class="topbar">
                                    <div class="wrapper full">
                                        <div class="welcome col" style="width: 570px; margin-top: 20px;">
                                            <!-- usuario logado-->
                                            
                                            <!-- fim usuario logado-->

                                            <!-- usuario não logado-->
                                            <div id="divTopoLogin" class="login col">
                                                <div id="Panel2" class="login-form">
	
                                                    <div style="display: none">
                                                        <label for="identificacao">Faça seu login:</label>
                                                        <input name="ctl00$TxtUsuario" type="text" id="TxtUsuario" class="campo_texto" autocomplete="off" placeholder="Digite seu email ou cpf" />
                                                    </div>
                                                    <div id="divPasswordDoLogin" style="display: none">
                                                        <label for="senha">Senha</label>
                                                        <input name="ctl00$TxtSenha" type="password" id="TxtSenha" class="campo_texto" />
                                                    </div>
                                                    
                                                    <a class="welcome-msg" style="font-size: 12px; vertical-align: middle; font-family: Tahoma"> OLÁ VISITANTE, </a> 
                                                    <a class="action-link criar-conta" style="font-size: 12px; font-family: Tahoma" id="btnBoxLogin" onclick="ExibirPopupLogin('../../../../../../../../Login/LoginBox.aspx',680,460)">FAÇA LOGIN</a> <a>|</a>
                                                    <a href="/cadastro/" class="action-link criar-conta" style="font-size: 12px; font-family: Tahoma">CRIAR CONTA</a> <a>|</a>
                                                    <div><a class="forgot-password action-link" href="#" style="font-size: 12px; font-family: Tahoma;vertical-align: middle;display: inline-block" onclick="ExibirPopup('../../../../../../../../login/ForgotPassWord.aspx',450,290)">ESQUECI MINHA SENHA</a> </div>
                                                      
</div>
                                            </div>

                                            

                               
                                           
                                        </div>
                                             <!-- fim usuario não logado -->
                                        <div class="televendas col" style="margin-top: 20px;">
                                            <p><span>Televendas:</span> <strong>4007-2526</strong></p>
                                        </div>
                                        
                                            <div class="social col" style="margin-top: 15px;">

                                                <ul class="social-list">
                                                    <li class="social-item"><a href="https://www.facebook.com/DrogariaOnofreOficial" class="social-link facebook" target="_blank" title="Facebook">Facebook</a></li>
                                                    <li class="social-item"><a href="https://www.instagram.com/drogariaonofre/" class="social-link instagram" target="_blank" title="Instagram">Instagram</a></li>
                                                    <li class="social-item"><a href="https://blogonofre.wordpress.com/" class="social-link beonofre" target="_blank" title="BlogOnofre">BeOnofre</a></li>
                                                    
                                                </ul>
                                            </div>
                                    </div>
                                </div>
                                <!-- /topbar -->
                                <div class="wrapper full">
                                    <div class="menu-responsive col" onclick="openNavMobile()"> </div>
                                    <div class="logo col">
                                        <h1>  <a href="https://www.onofre.com.br/" class="logo-img">Onofre</a>  </h1> </div>
                                    <div class="cart-responsive">
                                        <div class="cart col"> <a href="/carrinho" class="go-to-cart"><span class="total-value"> <span id="lblCartTotalResponsive">R$ 0,00</span> </span></a> </div>
                                    </div>
                                    <div class="search col">
                                        <div class="msg-cvs">
                                            <p> <img src="https://www.onofre.com.br/assets/img/cvs-health-logo.jpg" alt="CVS Health" width="105" height="21" /> A drogaria onofre agora faz parte da rede de farmácias CVS Health. <a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=230" class="action-link">Clique aqui e saiba mais.</a> </p>
                                        </div>
                                        <!-- /search -->
                                        <div class="search-box">
                                            <!-- search box starts here -->
                                            
                                         
                                             <div id="pnBuscaSli">
	
                                                <input type="hidden" name="asug"  />
                                                <input name="ctl00$sli_search_1" type="text" id="sli_search_1" data-provide="rac" value="Digite o nome do produto, marca ou princípio ativo..." class="search-field search-input" data-sli-test="searchbox" onblur="if(value==&#39;&#39;)value=&#39;Digite o nome do produto, marca ou princípio ativo...&#39;" onfocus="if(value==&#39;Digite o nome do produto, marca ou princípio ativo...&#39;)value=&#39;&#39;" onkeydown="javascript:return fnTrapKD(event,this)" autocomplete="off" /> <a id="btnOkSli" class="search-icon" href="javascript:SliSearchById('sli_search_1')" data-sli-test="searchbutton">Ok</a> 
</div>
                                          <!-- search box ends here -->
                                        </div>
                                    </div>
                                    <!-- /search -->
                                    <!-- carrinho -->
                                    <div class="cart col cart-normal"> <a href="/carrinho" class="go-to-cart"><span class="total-value"> <span id="lblShoppingCartTotal">R$ 0,00</span> </span></a>
                                        <div class="cart-hover">
                                            <div id="CartPopUp" class="cart-list">
                                                 </div>
                                            <div class="cart-bottom">
                                                <div class="line" style="display:none">
                                                     <span class="total">Total: <strong class="total-value"> <span id="lblCartTotal">R$ 0,00</span></strong></span>
                                                </div>
                                                <div class="line">
                                                    <!--<div class="one-click"><a href="" class="btn btn-gray buy-one-click">Comprar com 1 clique</a></div>-->
                                                    <div class="buy-cart"><a href="/carrinho" class="btn btn-green">Finalizar compra</a> </div>
                                                </div>
                                            </div> <span id="lblProdAdicionado" class="prod-added">Produto adicionado ao carrinho</span> </div>
                                    </div>
                                </div>
                                
                            </header>
        <nav id="main-nav" class="page-nav">
                                <div class="wrapper full">
                                    <ul class="nav-list">
                                        
                                        <li class="nav-item medicamentos-e-saude"><a href='https://www.onofre.com.br' title='Medicamentos e Saúde' class='nav-link'>Medicamentos</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Intestino e Digestão</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/saude-digestiva/44/03' class='medi-sub-nav-link' >Saúde Digestiva</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiflatulento/54/03' class='medi-sub-nav-link' >Antiflatulento</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiacido/95/03' class='medi-sub-nav-link' >Antiácido</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/laxante/248/03' class='medi-sub-nav-link' >Laxante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Diabetes</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipoglicemiante/234/03' class='medi-sub-nav-link' >Hipoglicemiante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Hormônios</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antigotoso/57/03' class='medi-sub-nav-link' >Antigotoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/tireoidiano/342/03' class='medi-sub-nav-link' >Tireoidiano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Infecções</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antibiotico/32/03' class='medi-sub-nav-link' >Antibiótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-infeccioso/67/03' class='medi-sub-nav-link' >Anti-infeccioso</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Aparelho Urinário</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidiuretico/46/03' class='medi-sub-nav-link' >Antidiurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antilitiasico/80/03' class='medi-sub-nav-link' >Antilitiásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/diuretico/190/03' class='medi-sub-nav-link' >Diurético</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/incontinencia-urinaria/242/03' class='medi-sub-nav-link' >Incontinência Urinária</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Nervoso</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivertiginoso/112/03' class='medi-sub-nav-link' >Antivertiginoso</a></li><li class='medi-sub-nav-item'><a href='/homeopaticos/calmante/147/03' class='medi-sub-nav-link' >Calmante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-tubo-neural/188/03' class='medi-sub-nav-link' >Distúrbio do Tubo Neural</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/neuropsicoestimulante/278/03' class='medi-sub-nav-link' >Neuropsicoestimulante</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Gripe e Resfriado</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitussigenos/109/03' class='medi-sub-nav-link' >Antitussígenos</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante/179/03' class='medi-sub-nav-link' >Descongestionante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/irritacoes-da-garganta/246/03' class='medi-sub-nav-link' >Irritações da Garganta</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/expectorante-e-mucolitico/274/03' class='medi-sub-nav-link' >Expectorante e Mucolítico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Anti-Hipertensivo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiarritmico/27/03' class='medi-sub-nav-link' >Antiarritmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hipertensivo/62/03' class='medi-sub-nav-link' >Anti-hipertensivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/cardiotonico/149/03' class='medi-sub-nav-link' >Cardiotônico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hipertensor/231/03' class='medi-sub-nav-link' >Hipertensor</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Cuidado com os Olhos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/orgaos-sensoriais/56/03' class='medi-sub-nav-link' >Órgãos Sensoriais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/descongestionante-ocular/180/03' class='medi-sub-nav-link' >Descongestionante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/distrofia-do-globo-ocular/189/03' class='medi-sub-nav-link' >Distrofia do Globo Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/lubrificante-ocular/260/03' class='medi-sub-nav-link' >Lubrificante Ocular</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Circulatório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antianemico/26/03' class='medi-sub-nav-link' >Antianêmico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-hemorragico/61/03' class='medi-sub-nav-link' >Anti-hemorrágico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antivaricoso/111/03' class='medi-sub-nav-link' >Antivaricoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hemostatico/221/03' class='medi-sub-nav-link' >Hemostático</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vermes e Parasitas</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifungico/52/03' class='medi-sub-nav-link' >Antifúngico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antimalarico/81/03' class='medi-sub-nav-link' >Antimalárico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparasitario/90/03' class='medi-sub-nav-link' >Antiparasitário</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Dor e Febre</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/analgesico/8/03' class='medi-sub-nav-link' >Analgésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anestesico/13/03' class='medi-sub-nav-link' >Anestésico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antienxaquecoso/48/03' class='medi-sub-nav-link' >Antienxaquecoso</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/anti-inflamatorio/69/03' class='medi-sub-nav-link' >Anti-inflamatório</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Alergias</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialergico/21/03' class='medi-sub-nav-link' >Antialérgico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Respiratório</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiasmatico/29/03' class='medi-sub-nav-link' >Antiasmático</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/broncodilatador/142/03' class='medi-sub-nav-link' >Broncodilatador</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Pele e Mucosa</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/cicatrizante/155/03' class='medi-sub-nav-link' >Cicatrizante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/despigmentante/182/03' class='medi-sub-nav-link' >Despigmentante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/aftas/215/03' class='medi-sub-nav-link' >Aftas</a></li><li class='medi-sub-nav-item'><a href='/tratamento-rosto/antiacne/399/03' class='medi-sub-nav-link' >Antiacne</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Vitaminas e Suplementos</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antifadiga/53/03' class='medi-sub-nav-link' >Antifadiga</a></li><li class='medi-sub-nav-item'><a href='/nutricosmeticos/antioxidante/88/03' class='medi-sub-nav-link' >Antioxidante</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/orexigeno/281/03' class='medi-sub-nav-link' >Orexígeno</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/vitaminico/367/03' class='medi-sub-nav-link' >Vitamínico</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Masculina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antialopecia/20/03' class='medi-sub-nav-link' >Antialopécia</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiandrogenico/24/03' class='medi-sub-nav-link' >Antiandrogénico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disfuncao-eretil/185/03' class='medi-sub-nav-link' >Disfunção Erétil</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/hiperplasia-prostatica-benigna/230/03' class='medi-sub-nav-link' >Hiperplasia Prostática Benigna</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Saúde Feminina</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/anticoncepcionais/39/03' class='medi-sub-nav-link' >Anticoncepcionais</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/disturbio-do-ciclo-menstrual/187/03' class='medi-sub-nav-link' >Distúrbio do Ciclo Menstrual</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/indutor-da-ovulacao/243/03' class='medi-sub-nav-link' >Indutor da Ovulação</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/terapeutica-da-menopausa/337/03' class='medi-sub-nav-link' >Terapêutica da Menopausa</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Sistema Ósseo</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiartrosico/28/03' class='medi-sub-nav-link' >Antiartrósico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiosteoporotico/87/03' class='medi-sub-nav-link' >Antiosteoporótico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/osteoporose/94/03' class='medi-sub-nav-link' >Osteoporose</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/repositor-de-potassio/315/03' class='medi-sub-nav-link' >Repositor de Potássio</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Controle Especial</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antidepressivo/42/03' class='medi-sub-nav-link' >Antidepressivo</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antiparkinsoniano/91/03' class='medi-sub-nav-link' >Antiparkinsoniano</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul><ul class='medi-sub-nav-col'><li class='medi-sub-nav-item-titulo'><p>Outros</p></li><li class='medi-sub-nav-item'><a href='/medicamentos/antineoplasico/84/03' class='medi-sub-nav-link' >Antineoplásico</a></li><li class='medi-sub-nav-item'><a href='/medicamentos/antitabagismo/103/03' class='medi-sub-nav-link' >Antitabagismo</a></li><li class='medi-sub-nav-item'><a href='/medicamento/55/01' class='medi-sub-nav-link-vejamais' >(+) Veja Mais</a></li></ul>
                                                     </div>
                                        </li>
                                        <li class="nav-item medicamentos-e-saude_new"><a href='https://www.onofre.com.br' title='Medicamentos e Saúde' class='nav-link'>Saúde</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class='sub-nav-item'><a href='/geriatria/46/01' class='sub-nav-link' title='Geriatria'>Geriatria</a></li><li class='sub-nav-item'><a href='/higiene-e-limpeza/48/01' class='sub-nav-link' title='Higiene e Limpeza'>Higiene e Limpeza</a></li><li class='sub-nav-item'><a href='/homeopaticos/50/01' class='sub-nav-link' title='Homeopáticos'>Homeopáticos</a></li><li class='sub-nav-item'><a href='/alimentos-e-bebidas/52/01' class='sub-nav-link' title='Alimentos e Bebidas'>Alimentos e Bebidas</a></li><li class='sub-nav-item'><a href='/medicamentos/55/01' class='sub-nav-link' title='Medicamentos'>Medicamentos</a></li><li class='sub-nav-item'><a href='/cuidado-com-os-olhos/57/01' class='sub-nav-link' title='Cuidado com os Olhos'>Cuidado com os Olhos</a></li><li class='sub-nav-item'><a href='/ortopedia-e-acessorios/58/01' class='sub-nav-link' title='Ortopedia e Acessórios'>Ortopedia e Acessórios</a></li><li class='sub-nav-item'><a href='/primeiros-socorros/60/01' class='sub-nav-link' title='Primeiros Socorros'>Primeiros Socorros</a></li><li class='sub-nav-item'><a href='/sexo-seguro/61/01' class='sub-nav-link' title='Sexo Seguro'>Sexo Seguro</a></li><li class='sub-nav-item'><a href='/fitness-e-dietas/62/01' class='sub-nav-link' title='Fitness e Dietas'>Fitness e Dietas</a></li><li class='sub-nav-item'><a href='/testes-e-aparelhos/63/01' class='sub-nav-link' title='Testes e Aparelhos'>Testes e Aparelhos</a></li><li class='sub-nav-item'><a href='/vitaminas-e-naturais/65/01' class='sub-nav-link' title='Vitaminas e Naturais'>Vitaminas e Naturais</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="A1"> <img id="Img1" /></a>
                                                    > </div>
                                            </div>
                                        </li>
                                        <li class="nav-item beleza-e-bem-estar"><a href='https://www.onofre.com.br' title='Beleza e Bem Estar' class='nav-link'>Beleza e Bem estar</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class='sub-nav-item'><a href='/tratamento-rosto/39/01' class='sub-nav-link' title='Tratamento Rosto'>Tratamento Rosto</a></li><li class='sub-nav-item'><a href='/cabelos/40/01' class='sub-nav-link' title='Cabelos'>Cabelos</a></li><li class='sub-nav-item'><a href='/corpo-e-banho/42/01' class='sub-nav-link' title='Corpo e Banho'>Corpo e Banho</a></li><li class='sub-nav-item'><a href='/cuidados-femininos/44/01' class='sub-nav-link' title='Cuidados Femininos'>Cuidados Femininos</a></li><li class='sub-nav-item'><a href='/cuidados-masculinos/49/01' class='sub-nav-link' title='Cuidados Masculinos'>Cuidados Masculinos</a></li><li class='sub-nav-item'><a href='/maos-e-pes/53/01' class='sub-nav-link' title='Mãos e Pés'>Mãos e Pés</a></li><li class='sub-nav-item'><a href='/maquiagem/54/01' class='sub-nav-link' title='Maquiagem'>Maquiagem</a></li><li class='sub-nav-item'><a href='/nutricosmeticos/56/01' class='sub-nav-link' title='Nutricosméticos'>Nutricosméticos</a></li><li class='sub-nav-item'><a href='/colonias/59/01' class='sub-nav-link' title='Colônias'>Colônias</a></li><li class='sub-nav-item'><a href='/tratamento-do-corpo/64/01' class='sub-nav-link' title='Tratamento do Corpo'>Tratamento do Corpo</a></li><li class='sub-nav-item'><a href='/higiene-bucal/68/01' class='sub-nav-link' title='Higiene Bucal'>Higiene Bucal</a></li><li class='sub-nav-item'><a href='/protecao-solar/69/01' class='sub-nav-link' title='Proteção Solar'>Proteção Solar</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="banner_menu_p2"> <img id="banner_menu_img2" /></a>
                                                     </div>
                                            </div>
                                        </li>
                                        <li class="nav-item mamae-e-bebe"><a href='https://www.onofre.com.br' title='Mamãe e Bebê' class='nav-link'>Mamãe e Bebê</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class='sub-nav-item'><a href='/acessorios-infantis/37/01' class='sub-nav-link' title='Acessórios Infantis'>Acessórios Infantis</a></li><li class='sub-nav-item'><a href='/alimentos-infantis/38/01' class='sub-nav-link' title='Alimentos Infantis'>Alimentos Infantis</a></li><li class='sub-nav-item'><a href='/corpo-e-banho-infantil/41/01' class='sub-nav-link' title='Corpo e Banho Infantil'>Corpo e Banho Infantil</a></li><li class='sub-nav-item'><a href='/cuidados-com-a-mamae/43/01' class='sub-nav-link' title='Cuidados com a Mamãe'>Cuidados com a Mamãe</a></li><li class='sub-nav-item'><a href='/troca-de-fraldas/45/01' class='sub-nav-link' title='Troca de Fraldas'>Troca de Fraldas</a></li><li class='sub-nav-item'><a href='/cuidado-bucal-infantil/47/01' class='sub-nav-link' title='Cuidado Bucal Infantil'>Cuidado Bucal Infantil</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="banner_menu_p3"> <img id="banner_menu_img3" /></a>
                                                     </div>
                                            </div>
                                        </li>
                                        <li class="nav-item ofertas-e-lancamentos"><a href='https://www.onofre.com.br' title ='Ofertas e Lançamentos' class='nav-link'>&nbsp&nbsp Ofertas e &nbsp&nbsp&nbsp&nbsp&nbsp<br /> &nbsp&nbsp Lançamentos</a>
                                            <div class="sub-nav" style="z-index:5003">
                                                <ul class="sub-nav-col">
                                                    <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/oferta/66" class="sub-nav-link" title="Ofertas">Ofertas</a></li>
                                                </ul>
                                                <ul class="sub-nav-col">
                                                    <li class="sub-nav-item"><a href="/Produtos/OfertasLancamentos/lancamento/66" class="sub-nav-link" title="Lançamentos">Lançamentos</a></li>
                                                </ul>
                                                <div class="banner-menu">
                                                    <a id="banner_menu_p4"> <img id="banner_menu_img4" /></a>
                                                     </div>
                                            </div>
                                        </li>
                                        <li class="nav-item como-comprar"><a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=251' title='Como Comprar' class='nav-link'>Como Comprar</a></li>
                                    </ul>
                                </div>
                            </nav>
        <div class="float-bar"></div>
        
        <!-- /floatbar -->
        <!-- FIM HEADER -->
        <!-- ESTRUTURA -->
        <div class="page-content">
            <div class="wrapper">
                <!-- conteudo -->
                
    <script>
  window.fbAsyncInit = function() {
    FB.init({
      appId      : '333327017122265',
      xfbml      : true,
      version    : 'v2.8'
    });
    FB.AppEvents.logPageView();
  };
</script>
    <!-- Load Facebook SDK for JavaScript -->
    <div id="fb-root"></div>
    <script>(function(d, s, id) {
      var js, fjs = d.getElementsByTagName(s)[0];
      if (d.getElementById(id)) return;
      js = d.createElement(s); js.id = id;
      js.src = "https://connect.facebook.net/pt_BR/sdk.js#xfbml=1&version=v2.8";
      fjs.parentNode.insertBefore(js, fjs);
    }(document, 'script', 'facebook-jssdk'));</script>

    <div class="page-content">
        <div class="wrapper">
            <input type="hidden" name="ctl00$cphConteudo$url" id="url" />
            <input type="hidden" name="ctl00$cphConteudo$hdAtivo" id="hdAtivo" />
            <ul class="breadcrumb full">
                <div id="breadcrumbs">
                    <a href="/Default.aspx">Drogaria Onofre</a> &#62; <a href=/medicamentos/55/01 class="bread_beleza">Medicamentos</a> &#62; <a href=/medicamentos/orgaos-sensoriais/56/03 class="bread_beleza">Órgãos Sensoriais</a>

                </div>
            </ul>
            <div class="main-product-image col9">
                <div class="main-image-wrap">
                    <!-- SELO PRODUTO -->
                    <div id="cphConteudo_seloProduto" style="background:white;border-radius:5px;color:white;text-align:center;">selo produto</div>
                    <!-- FIM SELO PRODUTO -->
                    <a href="https://www.onofre.com.br/estatico/Produto/Super/" id="cphConteudo_linkimgGrande" class="jqzoom" rel="gal1" title="">
                        <img id="cphConteudo_imgGrande" alt="Combigan Colírio Com 5ml" src="https://www.onofre.com.br/img/Busca/imagem_prescricao.jpg" height="480" width="480" />
                    </a></div>
                <input type="hidden" name="ctl00$cphConteudo$hf_id_produto" id="cphConteudo_hf_id_produto" value="8543" />
                <div class="img-thumbs">
                    <ul class="thumbs-list">
                        
                    </ul>
                </div>
            </div>
            <div class="main-product-info col7">
                <div class="flags"><span class="flag entrega-4horas">
                    </span> <span class="flag uso-adulto">
                        </span> </div>
                <div class="top-infos">
                    
                    <span class="code col">
                        <span id="cphConteudo_lblCode">Cód: 206180</span></span> <span class="ms col">
                            <span id="cphConteudo_num_registro"> MS: 1014701620019</span></span> </div>
                <h1 class="main-product-name">
                    <input type="hidden" name="ctl00$cphConteudo$ProductId" id="cphConteudo_ProductId" value="8543" />
                    <span id="lblProductName">Combigan Colírio Com 5ml</span></h1>
                
                <span id="cphConteudo_produtoAntibioticoAviso"></span>
                <span id="cphConteudo_listaProdutoAntbiotico"></span>
                <div class="top-infos">
                    <span id="cphConteudo_lblProductManufacturer"><a class="fabricante2" href="">Allergan</a></span>
                </div>
                <div class="product-spec">
                    <div id="DtlprinAtivo" class="spec principio-ativo">
                        <p class="spec-title col2">Princípio Ativo </p>
                        <p class="spec-text col5">
                            <span id="cphConteudo_lblDescriptionResume">Tartarato de Brimonidipina+Timolol</span>
                        </p>
                    </div>
                    
                    
                    
                    <a href="https://www.onofre.com.br/estatico/Bula/206180.pdf" id="bulaDetalhe" class="view-bula" target="_blank">Visualizar Bula do medicamento</a>
                    <div class="action-box">
                        
                        <div class="col3 dinheiro-extra" style="position: relative; margin-top: 10px;">
                            <div class="fb-save" data-uri="http://www.onofre.com.br/DetalheProduto/Default.aspx?ProductName=combigan-colirio-com-5ml&ProductId=8543" data-size="small"></div>
                            
                            
                            <div id="cphConteudo_divSemPBM" style="margin-top: -10px;"><small class="aviso">Preço válido para compras feitas pela internet. Imagem meramente ilustrativa.</small>
                                <!-- Campo CRM para medicamentos -->
                                <div id="cphConteudo_divCRM">
                                    <span id="cphConteudo_lblCrm">Insira o CRM do Médico:</span>
                                    <input name="ctl00$cphConteudo$txtCrm" type="text" id="cphConteudo_txtCrm" style="width: 100px; padding-bottom: -110px;" />&nbsp;
                                    <select name="ctl00$cphConteudo$slCrmUF" id="cphConteudo_slCrmUF" onchange="ValidarSelectCRM(this)">
	<option selected="selected" value="SP" disabled="">UF</option>
	<option value="AC">AC</option>
	<option value="AL">AL</option>
	<option value="AP">AP</option>
	<option value="AM">AM</option>
	<option value="BA">BA</option>
	<option value="CE">CE</option>
	<option value="DF">DF</option>
	<option value="ES">ES</option>
	<option value="GO">GO</option>
	<option value="MA">MA</option>
	<option value="MS">MS</option>
	<option value="MT">MT</option>
	<option value="MG">MG</option>
	<option value="PA">PA</option>
	<option value="PB">PB</option>
	<option value="PR">PR</option>
	<option value="PE">PE</option>
	<option value="PI">PI</option>
	<option value="RJ">RJ</option>
	<option value="RN">RN</option>
	<option value="RS">RS</option>
	<option value="RO">RO</option>
	<option value="RR">RR</option>
	<option value="SC">SC</option>
	<option value="SP">SP</option>
	<option value="SE">SE</option>
	<option value="TO">TO</option>
</select>
                                </div>
                                <!-- Fim Campo CRM para Medicamentos -->
                                <em>
                                    <span id="cphConteudo_lblMsg">Venda sob prescrição médica.</span></em> </div>

                            
                            <div id="divDescricaoDermaClub" onclick="$(this).hide();" style="width: 100%; height: 100%; position: fixed; top: 0; left: 0; background-color: rgba(255,255,255,0.6); padding-top: 10%; display: none; z-index: 5">
                                <div style="background-color: #99CCFF; border: 2px dashed #00B0F0; width: 500px; height: 250px; margin: 0 auto; color: white; font-weight: bold; z-index: 5; font-size: 19px; padding-top: 10px;"><span style="margin: 0 auto; width: 95%; display: block;">"O DermaClub é o clube de vantagens das marcas<br />
                                    La Roche-Posay, Vichy e SkinCeuticals, onde você pode acumular pontos em todas as suas compras e trocar por descontos e benefícios exclusivos. Além disso, você recebe dicas personalizadas sobre sua pele dos maiores dermatologistas do Brasil. Junte-se a nós e aproveite o máximo de vantagens para você e sua pele. Cadastre-se em <a style="text-decoration: none; color: white;" target="_blank" href="https://www.dermaclub.com.br">www.dermaclub.com.br</a>" </span></div>
                            </div>
                            <!--<div id="cphConteudo_divSeloDermaclu" onclick="window.open(&#39;/loginloreal.aspx&#39;,&#39;_self&#39;);" style="width: 225px; height: 115px; background-color: #FF7C80; padding-left: 4px; padding-right: 4px; padding-top: 4px; position: absolute; left: -65px; margin-top: 50px;">
                                <div style="background-color: white; width: 217px; height: 75px;">
                                    <div style="margin: 0 auto; width: 65%; padding-top: 12px;">
                                        <img style="float: left; margin-right: 4px;" alt="Promoção" height="24" src="/~/img/DetalheProduto/icone-medalha.png" />
                                        <img style="float: left; margin-right: 4px;" alt="DermaClub" height="13" src="/~/img/DetalheProduto/dermaclub-logo.png" />
                                        <div onmouseover="$('#divDescricaoDermaClub').show();" style="float: left; font-size: 10px; color: white; font-weight: 600; width: 12px; height: 12px; background-image: url('/~/img/DetalheProduto/interrogation-mark.png'); background-size: cover;"></div>
                                        <div style="float: left; font-size: 7px; font-weight: 800">COMPRE & GANHE <span style="color: #5EB1D9">0 PONTOS</span></div>
                                    </div>
                                    <p align="center" style="font-family: Arial; font-weight: 900; color: black; font-size: 12px; padding-top: 15px;">Comprar com desconto</p>
                                </div>
                                <p id="cphConteudo_pDescontoPorcentagemDermaclub" align="center" style="color: white; font-weight: bold; font-size: 25px;"></p>
                            </div>-->

                            

                        </div>

                         
                        <div id="cphConteudo_divBuyArea" class="col4 buy-area">
                            <div id="cphConteudo_divDropQuantidade"><span class="group-title">Selecione a
                                <span id="cphConteudo_lblDescEspeci">Quantidade</span>:</span>
                                <div class="sku-radio"><span class="group-name">
                                    <span id="cphConteudo_lblDescEspeci1">Quantidade</span></span>
                                    <div class="sku-list">
                                        <ul>
                                            
                                                    <li class="sku-item"><a href="/combigan-colirio-com-5ml/8543/05" id="Urlfilhos"> 
                                                        <label class="sku-name" for="beach"> 
                                                            <img id="cphConteudo_rptProdutoFilhos_imgEspe_0" Border="0" src="https://www.onofre.com.br/estatico/produto/especificacao/260.jpg" height="40" width="40" />
                                                            <span>5mL</span> </label>
                                                    </a></li>
                                                
                                        </ul>
                                    </div>
                                </div>
                            </div>
                            
                            <div id="cphConteudo_main_product" class="main-product-price"><span>
                                <label></label>
                            </span><span id="cphConteudo_old_price_span" class="old-price"><em>
                                <span id="cphConteudo_lblPrecoDe">R$ 103,17</span></em></span>  <span class="regular-price">
                                    <span id="cphConteudo_lblPrecoPor">R$ 79,44</span></span> </div>
                            <div id="cphConteudo_divComprar" class="buy-product buy-page">
                                <div id="cphConteudo_botao_quantidade_antigo" class="qtd">
                                    <div class="controls"><span onclick="incrementValue()">+</span> <span onclick="DecrementValue()">-</span> </div>
                                    <input name="ctl00$cphConteudo$txt_QtdDP" type="text" id="txt_QtdDP" value="1" class="qtd-field" readonly="readonly" />
                                </div>
                                <a href="javascript:chamarAjaxQtd('AddItem','[{idProduct:8543}]',parent.document.getElementById('txt_QtdDP').value);" id="cphConteudo_btComprarDP" class="btn-green btn-buy" onclick="SalvarCRMProduto">Comprar</a> </div>

                               <!--Quando o produto for derma club vai mostra um banner
                                <div style="top: 49%;left: 50%;margin-left: -25px;margin-top: 4px">
                                 <br />
                                         
                                 <a href="/loginloreal.aspx">
                                   <img id="derma-detalhe" style="display:none"   class="img-responsive" alt="derma club" src="../../img/DetalheProduto/dermaclub-detalhe.png"/>
                                  </a>
                                </div>  
                            -->
                               <!--*******************************************************************************-->


                            
                            
                            
                        </div>
                        <div>



 
                            
                        </div>
                        
                        

                        

                    </div>
                </div>
            </div>
            <div class="complementary row">
                
                <div id="AnvisaEtiquetaTextoSemBorda" class="AnvisaEtiquetaTextoSemBorda">
                    
                    
                </div>







                   </div>
            <div class="ch_clear" chaordic="top"></div>
            <div class="product-details tabs row col12">
                <nav class="tab-nav">
                    
                    <h2 id="cphConteudo_divDescricao_tab" class="tab-item active" data-item="descricao">Descrição do Produto</h2>
                    
                    
                </nav>
                
                <div id="cphConteudo_divDescricao" class="tab-content descricao active">
                    <p>
                        <div align="justify"><font color="#808080" face="Tahoma" size="2">combigan®</font><br><font color="#808080" face="Tahoma" size="2">tartarato de brimonidina 0,2%</font><br><font color="#808080" face="Tahoma" size="2">maleato de timolol 0,5%</font><br><font color="#808080" face="Tahoma" size="2">FORMA FARMACÊUTICA, VIA DE ADMINISTRAÇÃO E APRESENTAÇÃO</font><br><font color="#808080" face="Tahoma" size="2">Solução Oftálmica Estéril</font><br><font color="#808080" face="Tahoma" size="2">Via de administração tópica ocular</font><br><font color="#808080" face="Tahoma" size="2">Frasco plástico conta-gotas contendo 5ml ou 10ml de solução oftálmica estéril.</font><br><font color="#808080" face="Tahoma" size="2">1 gota = 0,042 ml</font><br><font color="#808080" face="Tahoma" size="2">USO ADULTO</font><br><font color="#808080" face="Tahoma" size="2">COMPOSIÇÃO</font><br><font color="#808080" face="Tahoma" size="2">SOLUÇÃO OFTÁLMICA</font><br><font color="#808080" face="Tahoma" size="2">tartarato de Brimonidina (1)..................................... 2,0 mg</font><br><font color="#808080" face="Tahoma" size="2">maleato de Timolol (2).............................................. 6,8 mg</font><br><font color="#808080" face="Tahoma" size="2">Excipientes (3) q.s.p...................................................1 ml</font><br><font color="#808080" face="Tahoma" size="2">(1) equivalente a 0,13% de brimonidina como base livre.</font><br><font color="#808080" face="Tahoma" size="2">(2) equivalente a 0,50% de timolol</font><br><font color="#808080" face="Tahoma" size="2">(3) Cloreto de benzalcônio, fosfato monobásico de sódio, fosfato dibásico de sódio, hidróxido de sódio, ácido clorídrico e água</font><br><font color="#808080" face="Tahoma" size="2">purificada.</font><br><font color="#808080" face="Tahoma" size="2">INFORMAÇÕES AO PACIENTE</font><br><font color="#808080" face="Tahoma" size="2">AÇÃO DO MEDICAMENTO</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN®(tartarato de brimonidina 0,2% e timolol 0,5%) é uma associação medicamentosa, que contém duas substâncias</font><br><font color="#808080" face="Tahoma" size="2">que agem de modo diferente para reduzir a pressão aumentada nos olhos, em indivíduos com glaucoma ou hipertensão</font><br><font color="#808080" face="Tahoma" size="2">ocular. Após a aplicação do colírio, o medicamento começa a agir rapidamente, atingindo pico máximo de ação dentro de</font><br><font color="#808080" face="Tahoma" size="2">uma a duas horas. A redução significativa da pressão ocular pode ser mantida por períodos tão longos quanto 12 horas.</font><br><font color="#808080" face="Tahoma" size="2">INDICAÇÕES DO MEDICAMENTO</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® é indicado para pacientes com glaucoma ou que apresentam pressão ocular aumentada e que podem correr</font><br><font color="#808080" face="Tahoma" size="2">risco de perder a visão. O produto tem a propriedade de reduzir a pressão ocular, de mantê-la em níveis normais, e evitar que</font><br><font color="#808080" face="Tahoma" size="2">ocorram as lesões nas estruturas oculares que levam à perda da visão.</font><br><font color="#808080" face="Tahoma" size="2">RISCOS DO MEDICAMENTO</font><br><font color="#808080" face="Tahoma" size="2">Contra-indicações</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® não pode ser usado em pessoas com:</font><br><font color="#808080" face="Tahoma" size="2">- asma brônquica ou outras doenças do pulmão como a doença pulmonar obstrutiva crônica grave,</font><br><font color="#808080" face="Tahoma" size="2">- doenças do coração como a bradicardia sinusal, bloqueio atrioventricular de 2º ou 3º grau, insuficiência cardíaca evidente,</font><br><font color="#808080" face="Tahoma" size="2">choque cardiogênico,</font><br><font color="#808080" face="Tahoma" size="2">- pacientes em tratamento com medicamentos do tipo inibidores da monoamino-oxidase (IMAO),</font><br><font color="#808080" face="Tahoma" size="2">- alergia a qualquer dos componentes da fórmula do produto.</font><br><font color="#808080" face="Tahoma" size="2">Converse com o seu médico para esclarecer dúvidas a respeito das condições clínicas descritas acima.</font><br><font color="#808080" face="Tahoma" size="2">Advertências</font><br><font color="#808080" face="Tahoma" size="2">Assim como para muitos outros medicamentos de uso tópico ocular, as substâncias presentes nesta associação podem ser</font><br><font color="#808080" face="Tahoma" size="2">absorvidas e agir em outros locais do organismo além dos olhos. Assim, podem causar algumas reações indesejáveis que</font><br><font color="#808080" face="Tahoma" size="2">são observadas quando essas substâncias são administradas por via oral.</font><br><font color="#808080" face="Tahoma" size="2">Por exemplo, após uso oral ou ocular de timolol, foram relatadas reações respiratórias graves e reações cardíacas. Em</font><br><font color="#808080" face="Tahoma" size="2">pessoas com asma brônquica foi relatado óbito por espasmo brônquico, e, em pessoas com insuficiência cardíaca, raramente,</font><br><font color="#808080" face="Tahoma" size="2">foi relatado óbito (ver CONTRA-INDICAÇÕES).</font><br><font color="#808080" face="Tahoma" size="2">Em pessoas que apresentam outras doenças, como por exemplo, doenças cardíacas, determinadas reações de tipo alérgico,</font><br><font color="#808080" face="Tahoma" size="2">glaucoma de ângulo fechado, doenças musculares caracterizadas por fraqueza muscular, diabetes, bronquite crônica,</font><br><font color="#808080" face="Tahoma" size="2">enfisema e outras doenças pulmonares, algumas doenças da tireóide, mau funcionamento do fígado ou dos rins, pessoas</font><br><font color="#808080" face="Tahoma" size="2">que precisarem de grandes cirurgias, pessoas com mau funcionamento vascular cerebral, entre outras, o uso de</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® requer cuidados especiais, que o seu médico saberá identificar.</font><br><font color="#808080" face="Tahoma" size="2">Precauções</font><br><font color="#808080" face="Tahoma" size="2">Você deve prestar atenção ao aplicar as gotas do colírio nos olhos e não encostar a ponta do frasco nos olhos ou ao redor</font><br><font color="#808080" face="Tahoma" size="2">dos olhos, nem em nenhuma outra superfície externa. O manuseio errado pode contaminar o colírio e causar infecções</font><br><font color="#808080" face="Tahoma" size="2">graves nos olhos que podem, inclusive, levar à perda da visão. Ocorreu infecção bacteriana dos olhos associada com o uso</font><br><font color="#808080" face="Tahoma" size="2">inadequado de frascos de colírios, que foram contaminados sem querer pelas pessoas. Procure imediatamente o seu médico</font><br><font color="#808080" face="Tahoma" size="2">para receber orientação adequada, se tiver algum traumatismo ou infecção, ou no caso de ser submetido a uma cirurgia nos</font><br><font color="#808080" face="Tahoma" size="2">olhos.</font><br><font color="#808080" face="Tahoma" size="2">Interações medicamentosas</font><br><font color="#808080" face="Tahoma" size="2">Informe o seu médico se estiver utilizando algum dos medicamentos ou substâncias mencionados a seguir, pois podem</font><br><font color="#808080" face="Tahoma" size="2">ocorrer interações entre eles e as substâncias que fazem parte da fórmula do COMBIGAN®:</font><br><font color="#808080" face="Tahoma" size="2">- medicamentos para a pressão arterial ou coração: anti-hipertensivos, glicosídeos cardíacos ou digitálicos, betabloqueadores,</font><br><font color="#808080" face="Tahoma" size="2">antagonistas do cálcio,</font><br><font color="#808080" face="Tahoma" size="2">- medicamentos para doenças do sistema nervoso: depressores do sistema nervoso central, como, por exemplo, os</font><br><font color="#808080" face="Tahoma" size="2">antidepressivos, barbituratos, opiáceos e sedativos.</font><br><font color="#808080" face="Tahoma" size="2">- medicamentos que contêm em sua fórmula a epinefrina, a clonidina, a quinidina ou a reserpina. Informe também o seu</font><br><font color="#808080" face="Tahoma" size="2">médico se costuma ingerir bebidas alcoólicas.</font><br><font color="#808080" face="Tahoma" size="2">Restrições a grupos de risco</font><br><font color="#808080" face="Tahoma" size="2">Não deve ser utilizado durante a gravidez e a amamentação, exceto sob orientação médica. Informe ao seu médico</font><br><font color="#808080" face="Tahoma" size="2">ou cirurgião dentista se ocorrer gravidez ou se iniciar a amamentação durante o uso deste medicamento.</font><br><font color="#808080" face="Tahoma" size="2">Este medicamento é contra-indicado na faixa etária de 0 a 12 anos.</font><br><font color="#808080" face="Tahoma" size="2">Informe ao seu médico ou cirurgião-dentista o aparecimento de reações indesejáveis.</font><br><font color="#808080" face="Tahoma" size="2">Informe ao seu médico ou cirurgião-dentista se você está fazendo uso de algum outro medicamento.</font><br><font color="#808080" face="Tahoma" size="2">Não use medicamento sem o conhecimento do seu médico. Pode ser perigoso para a sua saúde.</font><br><font color="#808080" face="Tahoma" size="2">MODO DE USO</font><br><font color="#808080" face="Tahoma" size="2">. COMBIGAN® é uma solução límpida de coloração amarelo-esverdeada.</font><br><font color="#808080" face="Tahoma" size="2">. Você deve usar este medicamento exclusivamente nos olhos.</font><br><font color="#808080" face="Tahoma" size="2">. A solução já vem pronta para uso. Não encoste a ponta do frasco nos olhos, nos dedos e nem em outra superfície qualquer,</font><br><font color="#808080" face="Tahoma" size="2">para evitar a contaminação do frasco e do colírio.</font><br><font color="#808080" face="Tahoma" size="2">. Você deve aplicar o número de gotas da dose recomendada pelo seu médico em um ou ambos os olhos. A dose usual é de 1</font><br><font color="#808080" face="Tahoma" size="2">gota aplicada no(s) olho(s) afetado(s), duas vezes ao dia.</font><br><font color="#808080" face="Tahoma" size="2">. COMBIGAN® é um medicamento de uso contínuo, e a duração do tratamento deve ser estabelecida pelo seu médico.</font><br><font color="#808080" face="Tahoma" size="2">. Se você usa lentes de contato gelatinosas ou hidrofílicas, tire as lentes antes de aplicar o COMBIGAN®. Aguarde pelo</font><br><font color="#808080" face="Tahoma" size="2">menos 15 minutos para recolocar as lentes após a aplicação do colírio.</font><br><font color="#808080" face="Tahoma" size="2">. Se você for utilizar COMBIGAN® concomitantemente com outros colírios, aguarde um intervalo de pelo 10 minutos entre a</font><br><font color="#808080" face="Tahoma" size="2">aplicação de cada medicamento.</font><br><font color="#808080" face="Tahoma" size="2">. Feche bem o frasco depois de usar.</font><br><font color="#808080" face="Tahoma" size="2">. Siga a orientação de seu médico, respeitando sempre os horários, as doses e a duração do tratamento.</font><br><font color="#808080" face="Tahoma" size="2">. Não interrompa o tratamento sem o conhecimento do seu médico.</font><br><font color="#808080" face="Tahoma" size="2">. Não use o medicamento com o prazo de validade vencido. Antes de usar observe o aspecto do medicamento.</font><br><font color="#808080" face="Tahoma" size="2">REAÇÕES ADVERSAS</font><br><font color="#808080" face="Tahoma" size="2">Nos estudos clínicos realizados com COMBIGAN® a maioria das reações indesejáveis foi transitória e não apresentou</font><br><font color="#808080" face="Tahoma" size="2">gravidade exigindo a interrupção do tratamento. As reações adversas mais freqüentemente relatadas foram, em ordem</font><br><font color="#808080" face="Tahoma" size="2">decrescente de incidência: sensação de ardor nos olhos, vermelhidão nos olhos, sensação de pontada nos olhos, distúrbios</font><br><font color="#808080" face="Tahoma" size="2">visuais, coceira ou prurido nos olhos, cansaço, dor de cabeça, olhos secos, lacrimejamento contínuo, ferida ou erosão da</font><br><font color="#808080" face="Tahoma" size="2">córnea, vermelhidão nas pálpebras, secreção nos olhos, inflamação das pálpebras, secura da boca, inchaço ou edema nas</font><br><font color="#808080" face="Tahoma" size="2">pálpebras, conjuntivite alérgica, dor ocular, entre outras.</font><br><font color="#808080" face="Tahoma" size="2">Avise o seu médico se aparecerem reações desagradáveis.</font><br><font color="#808080" face="Tahoma" size="2">ATENÇÃO: Este é um medicamento novo e, embora as pesquisas tenham indicado eficácia e segurança aceitáveis</font><br><font color="#808080" face="Tahoma" size="2">para comercialização, efeitos indesejáveis e não conhecidos podem ocorrer. Neste caso, informe seu médico.</font><br><font color="#808080" face="Tahoma" size="2">CONDUTA EM CASO DE SUPERDOSE</font><br><font color="#808080" face="Tahoma" size="2">Não foram relatados casos de superdose com COMBIGAN® solução oftálmica em humanos.</font><br><font color="#808080" face="Tahoma" size="2">A pessoa deve lavar bem os olhos com solução fisiológica, se usar uma dose maior do que a dose recomendada pelo médico,</font><br><font color="#808080" face="Tahoma" size="2">de modo intencional ou acidentalmente. Como podem aparecer as reações adversas descritas anteriormente, o médico deve</font><br><font color="#808080" face="Tahoma" size="2">ser consultado o mais rapidamente possível.</font><br><font color="#808080" face="Tahoma" size="2">CUIDADOS DE CONSERVAÇÃO E USO</font><br><font color="#808080" face="Tahoma" size="2">O frasco de COMBIGAN® solução oftálmica, antes ou depois de aberto, deve ser mantido em temperatura ambiente (entre</font><br><font color="#808080" face="Tahoma" size="2">15°C e 30°C) e protegido da luz.</font><br><font color="#808080" face="Tahoma" size="2">TODO MEDICAMENTO DEVE SER MANTIDO FORA DO ALCANCE DAS CRIANÇAS</font><br><font color="#808080" face="Tahoma" size="2">INFORMAÇÕES TÉCNICAS AOS PROFISSIONAIS DE SAÚDE</font><br><font color="#808080" face="Tahoma" size="2">1.CARACTERÍSTICAS FARMACOLÓGICAS</font><br><font color="#808080" face="Tahoma" size="2">Descrição</font><br><font color="#808080" face="Tahoma" size="2">Farmacodinâmica-Mecanismo de ação</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) é uma solução de uso oftálmico, que reduz a pressão intraocular</font><br><font color="#808080" face="Tahoma" size="2">(PIO) pela redução da produção de humor aquoso e pelo aumento do fluxo de saída uveoescleral, apresentando,</font><br><font color="#808080" face="Tahoma" size="2">portanto, propriedades antiglaucomatosas. É constituída pela combinação de um agonista alfa-2-adrenoceptor seletivo, a</font><br><font color="#808080" face="Tahoma" size="2">brimonidina (ou L-tartarato de 5-bromo-6-(2- imidazolidinil idenoamino) quinoxalina), mais um agente bloqueador dos</font><br><font color="#808080" face="Tahoma" size="2">receptores beta-adrenérgicos não seletivo, o timolol (ou, maleato de (-)-1-(terc-butilamino)-3-[(4-morfolino-1,2,5-tiadiazol-3-il)-</font><br><font color="#808080" face="Tahoma" size="2">oxi]-2-propanol). Essas substâncias são utilizadas individualmente para controlar a pressão intra-ocular em humanos.</font><br><font color="#808080" face="Tahoma" size="2">A pressão intra-ocular (PIO) elevada representa o principal fator de risco na perda de campo visual no glaucoma. Quanto</font><br><font color="#808080" face="Tahoma" size="2">maior o nível de pressão intra-ocular, maior a possibilidade de danos ao nervo óptico e perda do campo visual. COMBIGAN®</font><br><font color="#808080" face="Tahoma" size="2">(tartarato de brimonidina 0,2% e timolol 0,5%) é uma associação de duas substâncias com propriedades redutoras da</font><br><font color="#808080" face="Tahoma" size="2">pressão intra-ocular (PIO) através de mecanismos distintos. Tanto a brimonidina quanto o timolol apresentam um rápido início</font><br><font color="#808080" face="Tahoma" size="2">de ação, com efeito hipotensor ocular de pico observado em duas horas após a administração para a brimonidina e uma a</font><br><font color="#808080" face="Tahoma" size="2">duas horas para o timolol. A redução significativa da pressão ocular pode ser mantida por períodos tão longos quanto 12</font><br><font color="#808080" face="Tahoma" size="2">horas para a brimonidina e 24 horas para o timolol.</font><br><font color="#808080" face="Tahoma" size="2">A brimonidina é um potente agonista do receptor alfa-2-adrenérgico, que em estudos funcionais e de ligação com receptores</font><br><font color="#808080" face="Tahoma" size="2">radioativos é aproximadamente 1000 vezes mais seletiva para o adrenoceptor alfa-2 do que para o adrenoceptor alfa-1. As</font><br><font color="#808080" face="Tahoma" size="2">afinidades nos adrenoceptores humanos alfa-1 e alfa-2 são ~2000 nM e ~2 nM, respectivamente. Esta seletividade resulta em</font><br><font color="#808080" face="Tahoma" size="2">ausência de midríase e ausência de vasoconstrição em microvasos relacionados com enxertos retinianos humanos. Estudos</font><br><font color="#808080" face="Tahoma" size="2">fluorofotométricos realizados em animais e em humanos sugerem que o tartarato de brimonidina apresenta um duplo</font><br><font color="#808080" face="Tahoma" size="2">mecanismo de ação: reduz a pressão intra ocular por reduzir a produção do humor aquoso e aumentar o fluxo de saída</font><br><font color="#808080" face="Tahoma" size="2">uveoscleral não dependente da pressão.</font><br><font color="#808080" face="Tahoma" size="2">O timolol é um agente bloqueador dos receptores beta1 e beta2 adrenérgicos (não seletivo), que se combina de modo</font><br><font color="#808080" face="Tahoma" size="2">reversível com uma parte da membrana celular, o receptor beta-adrenérgico, e assim, inibe a resposta biológica usual que</font><br><font color="#808080" face="Tahoma" size="2">ocorre com a estimulação desse receptor. Este antagonismo competitivo bloqueia a estimulação dos receptores betaadrenérgicos</font><br><font color="#808080" face="Tahoma" size="2">por catecolaminas que apresentam atividade beta-adrenérgica estimulante (agonista), sejam elas originárias de</font><br><font color="#808080" face="Tahoma" size="2">uma fonte endógena ou exógena. A reversão deste bloqueio pode ser acompanhada pelo aumento das concentrações do</font><br><font color="#808080" face="Tahoma" size="2">agonista, que produzirá a restauração da resposta biológica usual.</font><br><font color="#808080" face="Tahoma" size="2">O mecanismo de ação exato do maleato de timolol na redução da pressão intra-ocular ainda não está totalmente esclarecido,</font><br><font color="#808080" face="Tahoma" size="2">embora um estudo com fluoresceína e estudos de tonografia tenham indicado que sua ação predominante pode estar</font><br><font color="#808080" face="Tahoma" size="2">relacionada com redução da formação de humor aquoso. A solução oftálmica de timolol a 0,5%, um beta-bloqueador não</font><br><font color="#808080" face="Tahoma" size="2">seletivo, reduz a PIO por diminuir a produção de humor aquoso.</font><br><font color="#808080" face="Tahoma" size="2">A administração tópica da solução oftálmica de brimonidina 0,2% diminui a pressão intra-ocular com mínimo efeito sobre os</font><br><font color="#808080" face="Tahoma" size="2">parâmetros cardiovasculares. A brimonidina 0,2% não apresenta efeitos sobre a função pulmonar ou taquicardia induzida por</font><br><font color="#808080" face="Tahoma" size="2">exercícios. Os efeitos cardiovasculares da brimonidina 0,2% durante o exercício em voluntários sadios se mostraram</font><br><font color="#808080" face="Tahoma" size="2">limitados a uma leve supressão da pressão arterial sistólica, que foi clinicamente irrelevante, durante o período de</font><br><font color="#808080" face="Tahoma" size="2">recuperação após teste em esteira. O timolol é um bloqueador dos receptores beta-adrenérgicos que não apresenta atividade</font><br><font color="#808080" face="Tahoma" size="2">simpatomimética intrínseca significativa, atividade de depressão direta do miocárdio, ou atividade anestésica local</font><br><font color="#808080" face="Tahoma" size="2">(estabilizador de membrana).</font><br><font color="#808080" face="Tahoma" size="2">Foi demonstrado em estudos experimentais em animais que a brimonidina apresenta uma atividade neuroprotetora potencial</font><br><font color="#808080" face="Tahoma" size="2">em animais nos quais a retina e o nervo óptico foram danificados. A brimonidina aumentou a sobrevida e a função das células</font><br><font color="#808080" face="Tahoma" size="2">ganglionares retinianas do rato após dano mecânico calibrado do nervo óptico. Em um outro modelo de estudo, a brimonidina</font><br><font color="#808080" face="Tahoma" size="2">melhorou o dano fotorreceptor induzido por 7 dias de exposição constante à luz. A sobrevivência das células fotorreceptoras</font><br><font color="#808080" face="Tahoma" size="2">foi aumentada pelo tartarato de brimonidina a 0,2% de modo dependente da dose. Em outro modelo animal, a brimonidina</font><br><font color="#808080" face="Tahoma" size="2">protegeu a estrutura interna e a função da retina contra danos isquêmicos devidos a pressão aguda induzida. O tartarato de</font><br><font color="#808080" face="Tahoma" size="2">brimonidina a 0,2% preservou a onda ERG-b (um índice de neuroproteção) após ser injetada por via intraperitonial em ratos.</font><br><font color="#808080" face="Tahoma" size="2">Os índices de recuperação da onda ERG-b que normalizaram para onda ERG-a foram de 87% no grupo de tratamento que</font><br><font color="#808080" face="Tahoma" size="2">recebeu 1 mg/kg de brimonidina, de 59% no grupo que recebeu 0,5 mg/kg, 31% no grupo que recebeu 0,1 mg/kg, em</font><br><font color="#808080" face="Tahoma" size="2">comparação com 15% no grupo controle. Sete e dez dias de aplicação tópica duas vezes ao dia de brimonidina preservaram</font><br><font color="#808080" face="Tahoma" size="2">significativamente a onda ERG-b normalizada em mais de 40%.</font><br><font color="#808080" face="Tahoma" size="2">Farmacocinética</font><br><font color="#808080" face="Tahoma" size="2">As concentrações plasmáticas da brimonidina e timolol foram determinadas em um estudo cruzado completo, envolvendo 16</font><br><font color="#808080" face="Tahoma" size="2">voluntários sadios tratados com COMBIGAN® e ALPHAGAN® 0,2% (solução oftálmica de tartarato de brimonidina), ou</font><br><font color="#808080" face="Tahoma" size="2">TIMOPTIC® (solução oftálmica USP 0,5% de maleato de timolol), em duas administrações ao dia, durante sete dias, em três</font><br><font color="#808080" face="Tahoma" size="2">períodos. Não foram detectadas diferenças estatisticamente significativas entre a ASC da brimonidina ou do timolol da</font><br><font color="#808080" face="Tahoma" size="2">associação presente no COMBIGAN® e das substâncias isoladamente, em monoterapia. Os valores da Cmax plasmática</font><br><font color="#808080" face="Tahoma" size="2">média de brimonidina nos grupos tratados com COMBIGAN® e ALPHAGAN® 0,2% (solução oftálmica de tartarato de</font><br><font color="#808080" face="Tahoma" size="2">brimonidina) foram 0,0327 ± 0,015 (média ± DP, N=15) e 0,0347 ± 0,0226 ng/ml (N=16), respectivamente, indicando ausência</font><br><font color="#808080" face="Tahoma" size="2">de diferença aparente. Os valores da Cmax plasmática média de timolol nos grupos tratados com COMBIGAN® e timolol</font><br><font color="#808080" face="Tahoma" size="2">0,5% foram 0,406 ± 0,216 (média ± DP, N=15) e 0,507 ± 0,269 ng/ml (N=14). Embora a Cmax do timolol tenha sido</font><br><font color="#808080" face="Tahoma" size="2">aproximadamente 20% mais baixa no grupo tratado com COMBIGAN®, esta diferença não foi estatisticamente significativa.</font><br><font color="#808080" face="Tahoma" size="2">(p=0,088).</font><br><font color="#808080" face="Tahoma" size="2">Após a aplicação ocular de COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) em voluntários sadios, a meia vida</font><br><font color="#808080" face="Tahoma" size="2">sistêmica aparente foi de 7 horas.</font><br><font color="#808080" face="Tahoma" size="2">A monitoração terapêutica do medicamento foi realizada em estudos clínicos de Fase III. As concentrações plasmáticas da</font><br><font color="#808080" face="Tahoma" size="2">brimonidina e timolol do grupo que recebeu COMBIGAN® duas vezes ao dia foram 15-49% mais baixas do que os respectivos</font><br><font color="#808080" face="Tahoma" size="2">valores em monoterapia. No caso da brimonidina, a diferença parece ser devida à administração de COMBIGAN® duas vezes</font><br><font color="#808080" face="Tahoma" size="2">ao dia e de ALPHAGAN® três vezes ao dia.</font><br><font color="#808080" face="Tahoma" size="2">As concentrações plasmáticas mais baixas de timolol observadas com COMBIGAN® em comparação com timolol 0,5%</font><br><font color="#808080" face="Tahoma" size="2">resultaram de absorção sistêmica mais lenta do timolol aparentemente devida à baixa concentração de cloreto de</font><br><font color="#808080" face="Tahoma" size="2">benzalcônio na fórmula do COMBIGAN® e não uma interação entre substâncias (brimonidina-timolol).</font><br><font color="#808080" face="Tahoma" size="2">Esses resultados de absorção sistêmica do medicamento tópico COMBIGAN® em comparação com os tratamentos em</font><br><font color="#808080" face="Tahoma" size="2">monoterapia são consistentes com o perfil mais favorável de segurança observado na comparação com ALPHAGAN® três</font><br><font color="#808080" face="Tahoma" size="2">vezes ao dia, e a segurança comparável quando COMBIGAN® foi comparado com o timolol duas vezes ao dia.</font><br><font color="#808080" face="Tahoma" size="2">A brimonidina foi absorvida sistemicamente em indivíduos jovens e em idosos após instilação ocular de tartarato de brimonidina</font><br><font color="#808080" face="Tahoma" size="2">a 0,2%. Entretanto, as concentrações no plasma foram baixas e a substância foi eliminada rapidamente da circulação sistêmica.</font><br><font color="#808080" face="Tahoma" size="2">As concentrações plasmáticas de pico foram atingidas dentro de 1-4 horas após a administração com um Tmax médio de 2</font><br><font color="#808080" face="Tahoma" size="2">horas. A meia vida aparente da brimonidina na circulação sistêmica foi em média de aproximadamente 3 horas após a</font><br><font color="#808080" face="Tahoma" size="2">administração ocular em dose única ou múltipla. A Cmax plasmática média da brimonidina foi de 0,0413 ng/ml para jovens e</font><br><font color="#808080" face="Tahoma" size="2">0,0524 ng/ml para idosos após dose única. Após administração de duas doses ao dia durante 10 dias, a Cmax plasmática média</font><br><font color="#808080" face="Tahoma" size="2">da brimonidina foi de 0,0585 ng/ml. A absorção e a eliminação sistêmicas não foram afetadas pela idade, bem como não foram</font><br><font color="#808080" face="Tahoma" size="2">observadas diferenças estatisticamente significativas no plasma com relação à Cmax, a meia-vida e à ASC da brimonidina.</font><br><font color="#808080" face="Tahoma" size="2">Após a administração tópica em humanos, a brimonidina apresenta ligação de aproximadamente 29% às proteínas</font><br><font color="#808080" face="Tahoma" size="2">plasmáticas. A proporção sangue-plasma da radioatividade total foi aproximadamente 1 após a administração oral de</font><br><font color="#808080" face="Tahoma" size="2">brimonidina-C14.</font><br><font color="#808080" face="Tahoma" size="2">A brimonidina não é metabolizada extensamente no olho humano, mas é extensamente metabolizada sistemicamente em</font><br><font color="#808080" face="Tahoma" size="2">humanos. A metabolização ocorre principalmente no fígado, mais provavelmente pelo citocromo P450 e aldeído oxidase.</font><br><font color="#808080" face="Tahoma" size="2">As principais vias metabólicas da brimonidina são a oxidação do carbono alfa da parte quinoxalina em derivado quinoxalino-</font><br><font color="#808080" face="Tahoma" size="2">2,3-diona e a quebra oxidativa do anel imidazolina em arilguanidina. Os metabólitos quinoxálicos são posteriormente</font><br><font color="#808080" face="Tahoma" size="2">metabolizados por glucoronidação.</font><br><font color="#808080" face="Tahoma" size="2">Após administração oral, a brimonidina e seus metabólitos são rapidamente eliminados da circulação sistêmica por excreção</font><br><font color="#808080" face="Tahoma" size="2">urinária em animais e humanos. Uma pequena fração da dose foi excretada inalterada na urina. Aproximadamente 87% da</font><br><font color="#808080" face="Tahoma" size="2">dose radioativa administrada oralmente foi eliminada em humanos dentro de 120 horas, sendo 74% encontrados na urina. A</font><br><font color="#808080" face="Tahoma" size="2">rápida eliminação pelo metabolismo sistêmico em metabólitos polares parece limitar a distribuição tissular e exposição</font><br><font color="#808080" face="Tahoma" size="2">corporal à brimonidina.</font><br><font color="#808080" face="Tahoma" size="2">A exposição sistêmica ao timolol após administração oral em humanos foi bem caracterizada. O timolol administrado por via</font><br><font color="#808080" face="Tahoma" size="2">oral é rapidamente e quase completamente absorvido (~ 90% de biodisponibilidade). Concentrações plasmáticas detectáveis</font><br><font color="#808080" face="Tahoma" size="2">de timolol ocorrem dentro de meia hora após a administração e as concentrações plasmáticas de pico ocorrem em cerca de</font><br><font color="#808080" face="Tahoma" size="2">uma a duas horas após a administração. A meia vida de eliminação aparente do timolol no plasma é de 4 horas. A meia vida é</font><br><font color="#808080" face="Tahoma" size="2">essencialmente inalterada em pacientes com insuficiência renal moderada.</font><br><font color="#808080" face="Tahoma" size="2">O timolol é metabolizado parcialmente no fígado e o timolol e seus metabólitos são excretados pelos rins. O timolol não se liga</font><br><font color="#808080" face="Tahoma" size="2">extensamente às proteínas plasmáticas (~ 60%). Após administração oral, o timolol sofre a um moderado metabolismo de</font><br><font color="#808080" face="Tahoma" size="2">primeira passagem (~ 50%). Apenas uma pequena quantidade da substância inalterada aparece na urina, juntamente com</font><br><font color="#808080" face="Tahoma" size="2">seus metabólitos após administração oral.</font><br><font color="#808080" face="Tahoma" size="2">Farmacocinética animal:</font><br><font color="#808080" face="Tahoma" size="2">A brimonidina e o timolol são rapidamente absorvidos após instilação tópica de dose única ou doses múltiplas de soluções</font><br><font color="#808080" face="Tahoma" size="2">oftálmicas em coelhos ou macacos. As concentrações tissulares de pico geralmente são atingidas dentro de 1 hora após a</font><br><font color="#808080" face="Tahoma" size="2">instilação. Um estudo sobre distribuição ocular da substância marcada radiativamente em coelhos brancos indicou um perfil de</font><br><font color="#808080" face="Tahoma" size="2">distribuição ocular semelhante para a brimonidina-C14 presente na associação em COMBIGAN® e no tartarato de brimonidina</font><br><font color="#808080" face="Tahoma" size="2">0,2% isolado, bem como um perfil de distribuição ocular semelhante para o timolol-H3 de COMBIGAN® e timolol 0,5%</font><br><font color="#808080" face="Tahoma" size="2">isoladamente. Tanto o timolol quanto a brimonidina são distribuídos a todas as partes do olho sendo que concentrações</font><br><font color="#808080" face="Tahoma" size="2">relativamente elevadas das substâncias são observadas na córnea, conjuntiva, íris, corpo ciliar e humor aquoso após</font><br><font color="#808080" face="Tahoma" size="2">administração de COMBIGAN®.</font><br><font color="#808080" face="Tahoma" size="2">Carcinogenicidade e Mutagenicidade</font><br><font color="#808080" face="Tahoma" size="2">Com o tartarato de brimonidina, não foram observados efeitos carcinogênicos em camundongos ou ratos após estudo de 21</font><br><font color="#808080" face="Tahoma" size="2">meses e de 24 meses, respectivamente. Nesses estudos, a administração de tartarato de brimonidina através da dieta, em</font><br><font color="#808080" face="Tahoma" size="2">doses de até 2,5 mg/kg/dia em camundongos e de 1,0 mg/kg/dia em ratos, atingiu 150 e 210 vezes, respectivamente, a</font><br><font color="#808080" face="Tahoma" size="2">concentração plasmática Cmax da substância observada após administração em humanos, tratados com uma gota de</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® em ambos os olhos, duas vezes ao dia.</font><br><font color="#808080" face="Tahoma" size="2">Em um estudo de dois anos sobre o maleato de timolol administrado por via oral em ratos, houve um aumento</font><br><font color="#808080" face="Tahoma" size="2">estatisticamente significativo na incidência de feocromocitomas adrenais em ratos machos que receberam 300 mg/kg/dia</font><br><font color="#808080" face="Tahoma" size="2">(aproximadamente 25.000 vezes maior que a exposição sistêmica após dose oftálmica diária recomendada em humanos).</font><br><font color="#808080" face="Tahoma" size="2">Diferenças semelhantes não foram observadas em ratos recebendo doses orais equivalentes a aproximadamente 8.300 vezes</font><br><font color="#808080" face="Tahoma" size="2">a dose oftálmica máxima recomendada para humanos.</font><br><font color="#808080" face="Tahoma" size="2">Em um estudo de sobrevida em camundongos, houve aumentos estatisticamente significativos na incidência de tumores</font><br><font color="#808080" face="Tahoma" size="2">pulmonares benignos e malignos, pólipos uterinos benignos e adenocarcinomas mamários em camundongos fêmea</font><br><font color="#808080" face="Tahoma" size="2">recebendo 500 mg/kg/dia (aproximadamente 42.000 vezes maior do que exposição sistêmica após administração de</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® na dose oftálmica recomendada para humanos). Em um estudo subsequente em camundongos fêmea, no qual</font><br><font color="#808080" face="Tahoma" size="2">o exame pós-morte foi limitado ao útero e pulmões, foi novamente observado um aumento estatisticamente significativo na</font><br><font color="#808080" face="Tahoma" size="2">incidência de tumores pulmonares com a dose de 500 mg/kg/dia.</font><br><font color="#808080" face="Tahoma" size="2">A ocorrência aumentada de adenocarcinomas mamários foi associada com elevações na prolactina sérica, a qual ocorreu em</font><br><font color="#808080" face="Tahoma" size="2">camundongos fêmea recebendo timolol por via oral na dose de 500mg/kg/dia, mas não com as doses de 5 ou 50 mg/kg/dia.</font><br><font color="#808080" face="Tahoma" size="2">Tem sido observado um aumento da incidência de adenocarcinomas mamários em roedores, associado com a administração</font><br><font color="#808080" face="Tahoma" size="2">de vários outros agentes terapêuticos que aumentam os níveis de prolactina, mas a correlação entre os níveis de prolactina e</font><br><font color="#808080" face="Tahoma" size="2">tumores mamários em humanos não foi estabelecida. Além disso, em mulheres adultas que receberam doses orais de até 60</font><br><font color="#808080" face="Tahoma" size="2">mg de maleato de timolol (que é a dose máxima recomendada em humanos), não houve alterações clinicamente relevantes da</font><br><font color="#808080" face="Tahoma" size="2">prolactina sérica.</font><br><font color="#808080" face="Tahoma" size="2">O tartarato de brimonidina não foi mutagênico ou clastogênico em uma série de estudos in vitro e in vivo, incluindo o teste de</font><br><font color="#808080" face="Tahoma" size="2">reversão bacteriana de Ames, a avaliação de aberrações cromossômicas em células de ovário de hamster chinês, em</font><br><font color="#808080" face="Tahoma" size="2">avaliação mediada por hospedeiro em camundongos CD-1, em avaliação citogenética em camundongos CD-1 e avaliação letal</font><br><font color="#808080" face="Tahoma" size="2">dominante em camundongos CD-1.</font><br><font color="#808080" face="Tahoma" size="2">O maleato de timolol foi desprovido de potencial mutagênico quando testado in vivo (camundongo) no teste de avaliação</font><br><font color="#808080" face="Tahoma" size="2">micronuclear e citogenética (doses até 800 mg/kg) e in vitro em avaliação de transformação de célula neoplásica (até 100</font><br><font color="#808080" face="Tahoma" size="2">?g/ml). Nos testes de Ames as concentrações empregadas de timolol mais elevadas, de 5.000 ou 10.000 ?g/placa foram</font><br><font color="#808080" face="Tahoma" size="2">associadas com elevações estatisticamente significativas de reversores observadas com as cepas de teste TA 100 (em sete</font><br><font color="#808080" face="Tahoma" size="2">avaliações de replicação), mas não nas três cepas restantes. Nas avaliações com a cepa de teste TA 100, não foi observada</font><br><font color="#808080" face="Tahoma" size="2">uma relação dose-resposta consistente, e a proporção de reversores de teste em relação aos controles não atingiu 2. A</font><br><font color="#808080" face="Tahoma" size="2">proporção de 2 usualmente é considerada como o critério para um teste Ames positivo.</font><br><font color="#808080" face="Tahoma" size="2">2. RESULTADOS DE EFICÁCIA</font><br><font color="#808080" face="Tahoma" size="2">Foram realizados estudos clínicos para avaliar a eficácia e segurança de COMBIGAN® (tartarato de brimonidina 0,2% e</font><br><font color="#808080" face="Tahoma" size="2">timolol 0,5%).1, 2, 3, 4 Um estudo de Fase II de 7 dias (N+73), com administração do medicamento duas vezes ao dia,</font><br><font color="#808080" face="Tahoma" size="2">comparou sua eficácia, segurança e tolerabilidade com a de uma solução oftálmica de tartarato de brimonidina 0,2%,</font><br><font color="#808080" face="Tahoma" size="2">administrada três vezes ao dia e timolol a 0,5% administrado duas vezes ao dia, ambos durante 7 dias. O estudo demonstrou</font><br><font color="#808080" face="Tahoma" size="2">que a administração em curto prazo de COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) foi bem tolerada com um</font><br><font color="#808080" face="Tahoma" size="2">perfil de segurança semelhante ao das substâncias isoladas, e proporcionou uma redução estatisticamente significativa e</font><br><font color="#808080" face="Tahoma" size="2">clinicamente relevante da pressão intra-ocular de até 7,8 mm Hg em relação ao basal em pacientes com glaucoma ou</font><br><font color="#808080" face="Tahoma" size="2">hipertensão ocular. 1</font><br><font color="#808080" face="Tahoma" size="2">Foram realizados dois estudos clínicos com duração de três meses e extensão para um ano (N=1.159) para avaliar a eficácia e</font><br><font color="#808080" face="Tahoma" size="2">segurança de COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) administrado duas vezes ao dia comparado com a</font><br><font color="#808080" face="Tahoma" size="2">brimonidina administrada três vezes ao dia e timolol administrado duas vezes ao dia em pacientes com glaucoma e</font><br><font color="#808080" face="Tahoma" size="2">hipertensão ocular.3, 4 A análise dos resultados indicou que COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%)</font><br><font color="#808080" face="Tahoma" size="2">proporcionou controle diurno da PIO consistente, sendo superior ao timolol e à brimonidina na redução da PIO elevada em</font><br><font color="#808080" face="Tahoma" size="2">pacientes com glaucoma e hipertensão ocular. Adicionalmente, COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%)</font><br><font color="#808080" face="Tahoma" size="2">administrado duas vezes ao dia apresentou um perfil de segurança favorável que foi comparável ao do timolol duas vezes ao</font><br><font color="#808080" face="Tahoma" size="2">dia e melhor do que a brimonidina administrada três vezes ao dia.3, 4</font><br><font color="#808080" face="Tahoma" size="2">A eficácia de COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) foi avaliada em comparação com os dois</font><br><font color="#808080" face="Tahoma" size="2">componentes da associação separadamente, através de três análises de pressão alvo: comparação da capacidade de reduzir</font><br><font color="#808080" face="Tahoma" size="2">a PIO durante o tratamento para as categorias de &lt;14 mmHg, 14 a 17,5 mmHg e &gt;17,5 mmHg; comparação da capacidade</font><br><font color="#808080" face="Tahoma" size="2">de atingir a pressão alvo de &lt; 18 mmHg. e comparação da capacidade de reduzir a PIO em mais de 20% em relação ao basal</font><br><font color="#808080" face="Tahoma" size="2">(baseado nas normas da Academia Americana de Oftalmologia, nas quais a redução de 20% em relação ao basal é</font><br><font color="#808080" face="Tahoma" size="2">considerada clinicamente significativa; Preferred Practice Pattern, 2000).</font><br><font color="#808080" face="Tahoma" size="2">Na primeira análise de pressão alvo, a distribuição dos pacientes em relação às categorias de PIO de &lt;14 mmHg, 14 a 17,5</font><br><font color="#808080" face="Tahoma" size="2">mmHg e &gt;17,5 mmHg, favoreceu COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) em relação a cada uma das</font><br><font color="#808080" face="Tahoma" size="2">monoterapias com os componentes da associação, com maior mudança estatisticamente significativa para as categorias de</font><br><font color="#808080" face="Tahoma" size="2">PIO mais baixa no grupo tratado com COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) do que nos grupos</font><br><font color="#808080" face="Tahoma" size="2">tratados com brimonidina ou com timolol (p&lt;0,001).</font><br><font color="#808080" face="Tahoma" size="2">A segunda análise de pressão alvo demonstrou que o tratamento com COMBIGAN® (tartarato de brimonidina 0,2% e timolol</font><br><font color="#808080" face="Tahoma" size="2">0,5%) reduziu a PIO para menos de 18 mmHg em maior porcentagem de pacientes do que o tratamento com brimonidina ou</font><br><font color="#808080" face="Tahoma" size="2">com timolol (p?0,015).</font><br><font color="#808080" face="Tahoma" size="2">Na terceira análise, o tratamento com COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) também reduziu a PIO</font><br><font color="#808080" face="Tahoma" size="2">mais de 20% em relação ao basal em maior porcentagem de pacientes do que os tratamentos com brimonidina ou com</font><br><font color="#808080" face="Tahoma" size="2">timolol (p?0,035).</font><br><font color="#808080" face="Tahoma" size="2">3. INDICAÇÕES</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) é indicado para reduzir a pressão intra-ocular elevada em</font><br><font color="#808080" face="Tahoma" size="2">pacientes com glaucoma crônico de ângulo aberto ou hipertensão ocular, que não respondem satisfatoriamente à</font><br><font color="#808080" face="Tahoma" size="2">monoterapia de redução da PIO, e quando o uso de COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) é</font><br><font color="#808080" face="Tahoma" size="2">considerado apropriado .</font><br><font color="#808080" face="Tahoma" size="2">4. CONTRA-INDICAÇÕES</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) é contra-indicado em pacientes com: asma brônquica,</font><br><font color="#808080" face="Tahoma" size="2">antecedentes de asma brônquica, doença pulmonar obstrutiva crônica grave, bradicardia sinusal, bloqueio atrioventricular de 2º</font><br><font color="#808080" face="Tahoma" size="2">ou 3º graus, insuficiência cardíaca evidente, choque cardiogênico, pacientes em tratamento com inibidores da monoaminooxidase</font><br><font color="#808080" face="Tahoma" size="2">(IMAO), hipersensibilidade a qualquer dos componentes da fórmula do produto.</font><br><font color="#808080" face="Tahoma" size="2">5. MODO DE USAR E CUIDADOS DE CONSERVAÇÃO DEPOIS DE ABERTO</font><br><font color="#808080" face="Tahoma" size="2">Condições de conservação: manter em temperatura ambiente (entre 15°C e 30°C) e proteger da luz.</font><br><font color="#808080" face="Tahoma" size="2">Manuseio e aplicação: a solução já vem pronta para uso. Para evitar contaminação, não encostar a ponta do frasco nos</font><br><font color="#808080" face="Tahoma" size="2">olhos, nos dedos e nem em outra superfície qualquer. Aplicar o número de gotas da dose recomendada em um ou ambos os</font><br><font color="#808080" face="Tahoma" size="2">olhos. COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) não deve ser aplicado durante o uso de lentes de contato,</font><br><font color="#808080" face="Tahoma" size="2">pois o cloreto de benzalcônio presente na fórmula pode ser absorvido pelas lentes de contato hidrofílicas. Os pacientes devem</font><br><font color="#808080" face="Tahoma" size="2">ser instruídos a aguardar pelo menos 15 minutos para recolocar as lentes após a administração do colírio. Fechar bem o frasco</font><br><font color="#808080" face="Tahoma" size="2">depois de usar. Se COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) for utilizado concomitantemente com outros</font><br><font color="#808080" face="Tahoma" size="2">medicamentos de aplicação tópica ocular, os produtos devem ser administrados com intervalos de pelo 10 minutos entre as</font><br><font color="#808080" face="Tahoma" size="2">aplicações.</font><br><font color="#808080" face="Tahoma" size="2">Via de administração: tópica oftálmica.</font><br><font color="#808080" face="Tahoma" size="2">6. POSOLOGIA</font><br><font color="#808080" face="Tahoma" size="2">A dose recomendada é de 1 gota no(s) olho(s) afetado(s), duas vezes ao dia (com intervalo aproximado de 12 horas entre as</font><br><font color="#808080" face="Tahoma" size="2">doses).</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) é solução de uso tópico, exclusivamente oftálmico, sendo</font><br><font color="#808080" face="Tahoma" size="2">medicamento de uso contínuo.</font><br><font color="#808080" face="Tahoma" size="2">7. ADVERTÊNCIAS</font><br><font color="#808080" face="Tahoma" size="2">Na presença de sinais de reações graves de hipersensibilidade, o tratamento deve ser interrompido. Assim como para muitos</font><br><font color="#808080" face="Tahoma" size="2">outros medicamentos de uso tópico oftálmico, adverte-se que as substâncias presentes nesta associação podem ser</font><br><font color="#808080" face="Tahoma" size="2">absorvidas sistemicamente.</font><br><font color="#808080" face="Tahoma" size="2">As mesmas reações adversas encontradas com a administração sistêmica de agentes bloqueadores beta-adrenérgicos</font><br><font color="#808080" face="Tahoma" size="2">podem ocorrer com a administração tópica. Por exemplo, foram relatados após administração sistêmica ou oftálmica de</font><br><font color="#808080" face="Tahoma" size="2">timolol, reações respiratórias graves e reações cardíacas, incluindo óbito por broncoespasmo em pacientes com asma</font><br><font color="#808080" face="Tahoma" size="2">brônquica, e, raramente óbito em associação com insuficiência cardíaca, (ver CONTRA-INDICAÇÕES).</font><br><font color="#808080" face="Tahoma" size="2">Cardíacas: Insuficiência cardíaca: por causa da presença do timolol na fórmula, a insuficiência cardíaca deve ser controlada</font><br><font color="#808080" face="Tahoma" size="2">adequadamente antes de iniciar o tratamento com COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%). Em pacientes</font><br><font color="#808080" face="Tahoma" size="2">com história de doença cardíaca grave, devem-se procurar sinais de insuficiência cardíaca e verificar a freqüência do pulso.</font><br><font color="#808080" face="Tahoma" size="2">Recomenda-se cautela no tratamento de pacientes com doenças cardiovasculares graves.</font><br><font color="#808080" face="Tahoma" size="2">Pâncreas: Diabetes mellitus: os agentes bloqueadores beta-adrenérgicos devem ser utilizados com cautela em pacientes</font><br><font color="#808080" face="Tahoma" size="2">sujeitos a hipoglicemia espontânea ou em pacientes diabéticos (especialmente aqueles com diabetes lábil) que estejam</font><br><font color="#808080" face="Tahoma" size="2">recebendo insulina ou agentes hipoglicemiantes orais. Os agentes bloqueadores dos receptores beta-adrenérgicos podem</font><br><font color="#808080" face="Tahoma" size="2">mascarar os sinais e sintomas da hipoglicemia aguda.</font><br><font color="#808080" face="Tahoma" size="2">Oculares: Glaucoma de ângulo fechado: COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) não deve ser utilizado</font><br><font color="#808080" face="Tahoma" size="2">isoladamente no tratamento do glaucoma de ângulo fechado.</font><br><font color="#808080" face="Tahoma" size="2">Precauções</font><br><font color="#808080" face="Tahoma" size="2">Gerais</font><br><font color="#808080" face="Tahoma" size="2">Pacientes tratados com medicamentos redutores da pressão intra-ocular (PIO) devem ser rotineiramente monitorados com</font><br><font color="#808080" face="Tahoma" size="2">relação à medida da PIO.</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) deve ser utilizado com cautela em pacientes com depressão,</font><br><font color="#808080" face="Tahoma" size="2">insuficiência cerebral ou coronariana, fenômeno de Raynaud, hipotensão ortostática, ou tromboangeíte obliterante.</font><br><font color="#808080" face="Tahoma" size="2">Houve relatos de ceratite bacteriana associada com o uso de recipientes de doses múltiplas de produtos oftálmicos de uso</font><br><font color="#808080" face="Tahoma" size="2">tópico. Esses recipientes foram contaminados inadvertidamente pelos pacientes, que, na maioria dos casos, apresentam</font><br><font color="#808080" face="Tahoma" size="2">doença corneana concomitante ou ruptura da superfície epitelial ocular.</font><br><font color="#808080" face="Tahoma" size="2">Hipersensibilidade: considerando a presença da brimonidina na fórmula, COMBIGAN® (tartarato de brimonidina 0,2% e</font><br><font color="#808080" face="Tahoma" size="2">timolol 0,5%) deve ser utilizado com cautela em pacientes com hipersensibilidade conhecida a outros agonistas alfaadrenoceptores.</font><br><font color="#808080" face="Tahoma" size="2">Anafilaxia: durante o tratamento com beta-bloqueadores, os pacientes com antecedentes de atopia ou de</font><br><font color="#808080" face="Tahoma" size="2">reações anafiláticas graves a vários alergenos, podem se mostrar mais reativos à provocação repetida acidental, com fins</font><br><font color="#808080" face="Tahoma" size="2">diagnósticos, ou terapêuticos com tais alergenos. Tais pacientes podem não responder às doses usuais de epinefrina</font><br><font color="#808080" face="Tahoma" size="2">utilizada para tratar reações anafiláticas uma vez que o timolol pode abrandar os efeitos beta-agonistas da epinefrina. Em tais</font><br><font color="#808080" face="Tahoma" size="2">casos deve-se considerar medidas alternativas à epinefrina. .</font><br><font color="#808080" face="Tahoma" size="2">Uso de lentes de contato: COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) contém cloreto de benzalcônio como</font><br><font color="#808080" face="Tahoma" size="2">conservante, que pode ser depositado em lentes hidrofílicas. Por isso não deve ser administrado durante o uso das lentes de</font><br><font color="#808080" face="Tahoma" size="2">contacto, que devem ser retiradas antes da aplicação do colírio e não recolocadas antes de 15 minutos após a administração.</font><br><font color="#808080" face="Tahoma" size="2">Descolamento coroidal</font><br><font color="#808080" face="Tahoma" size="2">Foram relatados casos de separação coroidal após cirurgias filtrantes com a administração de tratamento supressor de</font><br><font color="#808080" face="Tahoma" size="2">produção de humor aquoso (ex.: timolol e acetazolamida). O tratamento de olhos com separação coriodal crônica ou</font><br><font color="#808080" face="Tahoma" size="2">recorrente, deve incluir a interrupção de todas as formas de tratamento supressor da produção de humor aquoso e o</font><br><font color="#808080" face="Tahoma" size="2">tratamento intensivo da inflamação endógena.</font><br><font color="#808080" face="Tahoma" size="2">Cirurgias: Grandes cirurgias: há controvérsias sobre a necessidade ou o desejo de se suspender o uso de agentes</font><br><font color="#808080" face="Tahoma" size="2">bloqueadores beta-adrenérgicos antes de grandes cirurgias. Se necessário, durante a cirurgia, os efeitos dos agentes</font><br><font color="#808080" face="Tahoma" size="2">bloqueadores dos receptores beta-adrenérgicos podem ser revertidos pela administração de doses suficientes de agonistas</font><br><font color="#808080" face="Tahoma" size="2">adrenérgicos.</font><br><font color="#808080" face="Tahoma" size="2">Tireóide: Tireotoxicose: os agentes bloqueadores beta-adrenérgicos podem mascarar determinados sinais clínicos (ex.:</font><br><font color="#808080" face="Tahoma" size="2">taquicardia) de hipertireoidismo. Pacientes com suspeita de desenvolver tireotoxicose devem ser tratados cuidadosamente</font><br><font color="#808080" face="Tahoma" size="2">para evitar suspensão repentina dos agentes bloqueadores beta-adrenérgicos que podem precipitar crise tireoidiana.</font><br><font color="#808080" face="Tahoma" size="2">Músculo-esqueléticas: Fraqueza muscular: foi relatado que o bloqueio beta-adrenérgico potencializa a fraqueza muscular</font><br><font color="#808080" face="Tahoma" size="2">compatível com determinados sintomas miastênicos (ex.: diplopia, ptose e fraqueza generalizada). Foi relatado que o timolol</font><br><font color="#808080" face="Tahoma" size="2">raramente aumenta a fraqueza muscular em alguns pacientes com miastenia gravis ou sintomas miastênicos.</font><br><font color="#808080" face="Tahoma" size="2">Cerebrovasculares: Insuficiência vascular cerebral: Considerando os efeitos potenciais dos agentes bloqueadores betaadrenérgicos</font><br><font color="#808080" face="Tahoma" size="2">sobre a pressão arterial e o pulso, esses agentes devem ser utilizados com cautela em pacientes com</font><br><font color="#808080" face="Tahoma" size="2">insuficiência vascular cerebral. Se ocorrerem sinais e sintomas sugerindo desenvolvimento de redução do fluxo cerebral após</font><br><font color="#808080" face="Tahoma" size="2">o início do tratamento com COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%), deve-se considerar um tratamento</font><br><font color="#808080" face="Tahoma" size="2">alternativo.</font><br><font color="#808080" face="Tahoma" size="2">Fígado e rins: não foi estudado o emprego de COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) em pacientes</font><br><font color="#808080" face="Tahoma" size="2">com insuficiência hepática ou renal; recomenda-se cautela ao tratar tais pacientes.</font><br><font color="#808080" face="Tahoma" size="2">Gestação e lactação</font><br><font color="#808080" face="Tahoma" size="2">Categoria de risco na gravidez: C (FDA - USA)</font><br><font color="#808080" face="Tahoma" size="2">Não foram realizados estudos adequados e controlados sobre o uso de COMBIGAN® (tartarato de brimonidina 0,2% e timolol</font><br><font color="#808080" face="Tahoma" size="2">0,5%) em mulheres grávidas. Considerando que os estudos de reprodução em animais nem sempre podem prever a resposta</font><br><font color="#808080" face="Tahoma" size="2">humana, COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) deve ser utilizado durante a gestação apenas se os</font><br><font color="#808080" face="Tahoma" size="2">potenciais benefícios para a mãe justificarem os potenciais riscos para o feto.</font><br><font color="#808080" face="Tahoma" size="2">O timolol foi detectado no leite humano após administração oral e tópica oftálmica. Desconhece-se se o tartarato de</font><br><font color="#808080" face="Tahoma" size="2">brimonidina é ou não excretado no leite humano, embora tenha sido demonstrada a excreção do tartarato de brimonidina no</font><br><font color="#808080" face="Tahoma" size="2">leite em animais. Considerando as potenciais reações adversas graves do timolol ou do tartarato de brimonidina em lactentes,</font><br><font color="#808080" face="Tahoma" size="2">deve-se ponderar sobre a possibilidade de suspender o tratamento ou a amamentação, levando em consideração a</font><br><font color="#808080" face="Tahoma" size="2">importância do medicamento para a mãe.</font><br><font color="#808080" face="Tahoma" size="2">8. USO EM IDOSOS, CRIANÇAS E OUTROS GRUPOS DE RISCO.</font><br><font color="#808080" face="Tahoma" size="2">Pacientes idosos</font><br><font color="#808080" face="Tahoma" size="2">De modo geral não foram observadas diferenças entre pacientes idosos e pacientes adultos de outras faixas etárias. A Cmax e</font><br><font color="#808080" face="Tahoma" size="2">meia vida aparente da brimonidina foram semelhantes em indivíduos idosos (65 anos de idade ou mais) e adultos mais jovens,</font><br><font color="#808080" face="Tahoma" size="2">indicando que sua absorção sistêmica e eliminação não foram significativamente afetadas pela idade.</font><br><font color="#808080" face="Tahoma" size="2">Pacientes pediátricos</font><br><font color="#808080" face="Tahoma" size="2">O uso de COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) em pacientes pediátricos, atualmente, não é</font><br><font color="#808080" face="Tahoma" size="2">recomendado (ver ADVERTÊNCIAS). Foram relatados vários eventos adversos graves em associação com a administração</font><br><font color="#808080" face="Tahoma" size="2">de solução de tartarato de brimonidina a 0,2% em lactentes com idades entre 28 dias e 3 meses. (ver REAÇOES</font><br><font color="#808080" face="Tahoma" size="2">ADVERSAS)</font><br><font color="#808080" face="Tahoma" size="2">Operar máquinas e dirigir automóvel:</font><br><font color="#808080" face="Tahoma" size="2">O uso de COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) pode potencialmente causar fadiga e/ou sonolência em</font><br><font color="#808080" face="Tahoma" size="2">alguns pacientes. Pacientes que forem exercer atividades de risco, como dirigir automóveis ou operar máquinas, devem ser</font><br><font color="#808080" face="Tahoma" size="2">alertados quanto à possibilidade de apresentarem diminuição do alerta mental durante o tratamento.</font><br><font color="#808080" face="Tahoma" size="2">9. INTERAÇÕES MEDICAMENTOSAS</font><br><font color="#808080" face="Tahoma" size="2">Anti-hipertensivos / glicosídeos cardíacos: considerando que COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%)</font><br><font color="#808080" face="Tahoma" size="2">pode reduzir a pressão arterial, recomenda-se cautela no uso concomitante com medicamentos tais como anti-hipertensivos</font><br><font color="#808080" face="Tahoma" size="2">e/ou glicosídeos cardíacos.</font><br><font color="#808080" face="Tahoma" size="2">Bloqueadores beta-adrenérgicos: pacientes que estejam recebendo agentes bloqueadores beta-adrenérgicos por via oral e</font><br><font color="#808080" face="Tahoma" size="2">timolol por via tópica devem ser observados quanto ao potencial de provocarem efeitos aditivos de bloqueio beta-adrenérgico</font><br><font color="#808080" face="Tahoma" size="2">tanto sistêmico quanto sobre a pressão intra-ocular. O uso concomitante de dois bloqueadores beta-adrenérgicos tópicos não</font><br><font color="#808080" face="Tahoma" size="2">é recomendado.</font><br><font color="#808080" face="Tahoma" size="2">Antagonistas do cálcio ou Medicamentos depletivos de catecolaminas: Recomenda-se cuidadosa monitoração dos</font><br><font color="#808080" face="Tahoma" size="2">pacientes quando o maleato de timolol é administrado a pacientes que estejam recebendo bloqueadores dos canais de cálcio</font><br><font color="#808080" face="Tahoma" size="2">orais ou intravenosos e medicamentos que causam depleção de catecolaminas, tais como, reserpina, ou agentes bloqueadores</font><br><font color="#808080" face="Tahoma" size="2">beta-adrenérgicos. Existe a possibilidade de ocorrerem efeitos aditivos e a produção de hipotensão, distúrbios da condução</font><br><font color="#808080" face="Tahoma" size="2">atrioventricular, insuficiência ventricular esquerda e/ou bradicardia acentuada.</font><br><font color="#808080" face="Tahoma" size="2">Depressores do sistema nervoso central: embora não tenham sido realizados estudos específicos sobre interações com</font><br><font color="#808080" face="Tahoma" size="2">COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) e depressores do SNC (álcool, barbituratos, opiáceos, sedativos,</font><br><font color="#808080" face="Tahoma" size="2">ou anestésicos), a possibilidade de um efeito aditivo ou de potencialização deve ser considerada.</font><br><font color="#808080" face="Tahoma" size="2">Epinefrina: foi relatada, ocasionalmente, midríase resultante do tratamento concomitante de timolol com epinefrina.</font><br><font color="#808080" face="Tahoma" size="2">Quinidina: o bloqueio beta adrenérgico potencializado (ex.: freqüência cardíaca diminuída) foi relatado durante o tratamento</font><br><font color="#808080" face="Tahoma" size="2">combinado de quinidina com timolol, possivelmente porque a quinidina inibe o metabolismo do timolol através das enzimas P-</font><br><font color="#808080" face="Tahoma" size="2">450, CYP2D6.</font><br><font color="#808080" face="Tahoma" size="2">Clonidina: os agentes bloqueadores adrenérgicos podem exacerbar a hipertensão de rebote que pode seguir a suspensão da</font><br><font color="#808080" face="Tahoma" size="2">clonidina. Não houve relatos de exacerbação da hipertensão de rebote com maleato de timolol oftálmico.</font><br><font color="#808080" face="Tahoma" size="2">Antidepressivos tricíclicos: foi relatado que os antidepressivos tricíclicos abrandam o efeito hipotensor da clonidina</font><br><font color="#808080" face="Tahoma" size="2">sistêmica. Não se sabe se o uso concomitante desses agentes com COMBIGAN® (tartarato de brimonidina 0,2% e timolol</font><br><font color="#808080" face="Tahoma" size="2">0,5%) em humanos pode resultar em interferência no efeito redutor da PIO.</font><br><font color="#808080" face="Tahoma" size="2">Não se dispõe de dados sobre o nível de catecolaminas circulantes após administração de COMBIGAN® (tartarato de</font><br><font color="#808080" face="Tahoma" size="2">brimonidina 0,2% e timolol 0,5%). Entretanto, recomenda-se cautela em pacientes recebendo antidepressivos tricíclicos que</font><br><font color="#808080" face="Tahoma" size="2">podem ou não afetar o metabolismo de recaptação de aminas circulantes.</font><br><font color="#808080" face="Tahoma" size="2">10. REAÇÕES ADVERSAS A MEDICAMENTOS</font><br><font color="#808080" face="Tahoma" size="2">Nos estudos clínicos realizados com COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) a maioria das reações</font><br><font color="#808080" face="Tahoma" size="2">adversas foi transitória e não apresentou gravidade exigindo a interrupção do tratamento. Nos estudos clínicos, COMBIGAN®</font><br><font color="#808080" face="Tahoma" size="2">(tartarato de brimonidina 0,2% e timolol 0,5%) se mostrou seguro e bem tolerado, com um perfil de segurança aceitável. Não</font><br><font color="#808080" face="Tahoma" size="2">foram observadas reações adversas exclusivas da combinação do tartarato de brimonidina com timolol. Todas as reações</font><br><font color="#808080" face="Tahoma" size="2">haviam sido relatadas para a brimonidina 0,2% ou timolol 0,5%, embora com incidências diferentes.</font><br><font color="#808080" face="Tahoma" size="2">As reações adversas em dois estudos clínicos incluindo ao todo 385 pacientes tratados com COMBIGAN® (tartarato de</font><br><font color="#808080" face="Tahoma" size="2">brimonidina 0,2% e timolol 0,5%) por até 12 meses, os eventos adversos relacionados ao tratamento relatados para a</font><br><font color="#808080" face="Tahoma" size="2">combinação e para a brimonidina e timolol individualmente foram os seguintes:</font><br><font color="#808080" face="Tahoma" size="2">a = sistemas do organismo e termos preferidos pelo dicionário COSTART modificado pela Allergan.</font><br><font color="#808080" face="Tahoma" size="2">b = incidência com Combigan foi significativamente mais baixa do que com monoterapia (p?0,05)</font><br><font color="#808080" face="Tahoma" size="2">c = incidência com Combigan foi significativamente mais elevada do que com monoterapia (p?0,05)</font><br><font color="#808080" face="Tahoma" size="2">Eventos adversos adicionais que foram relatados com um dos dois componentes e podem se constituir em potenciais</font><br><font color="#808080" face="Tahoma" size="2">reações adversas de COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) são:</font><br><font color="#808080" face="Tahoma" size="2">Tartarato de brimonidina: Eventos relatados em &gt;1% e &lt;8% dos pacientes tratados com Alphagan® (tartarato de brimonidina</font><br><font color="#808080" face="Tahoma" size="2">) solução oftálmica a 0,2% incluem: tontura, sintomas respiratórios das vias aéreas superiores, sintomas gastrintestinais,</font><br><font color="#808080" face="Tahoma" size="2">alteração do paladar, secura nasal, fotofobia, lacrimejamento, edema conjuntival, vasoconstrição conjuntival, papilas</font><br><font color="#808080" face="Tahoma" size="2">conjuntivais e alteração da visão , entre outros.</font><br><font color="#808080" face="Tahoma" size="2">Maleato de Timolol: Administração ocular:</font><br><font color="#808080" face="Tahoma" size="2">Cardiovasculares: eventos adversos relatados com o timolol incluem agravamento ou desencadeamento de determinados</font><br><font color="#808080" face="Tahoma" size="2">distúrbios cardiovasculares. Pulmonares e outros, relacionados aos efeitos de bloqueio beta sistêmico (ver CONTRAINDICAÇÕES</font><br><font color="#808080" face="Tahoma" size="2">E PRECAUÇÕES), incluindo arritmia, bradicardia, parada cardíaca, insuficiência cardíaca congestiva, acidente</font><br><font color="#808080" face="Tahoma" size="2">vascular cerebral, isquemia cerebral, mãos e pés frios, edema, bloqueio cardíaco, hipotensão, palpitação, claudicação,</font><br><font color="#808080" face="Tahoma" size="2">fenômeno de Raynaud, síncope.</font><br><font color="#808080" face="Tahoma" size="2">Endócrinas: mascaramento de sintomas de hipoglicemia em pacientes diabéticos (ver ADVERTÊNCIAS).</font><br><font color="#808080" face="Tahoma" size="2">Respiratórias: broncoespasmo (predominantemente em pacientes com doenças broncoespásticas preexistentes),</font><br><font color="#808080" face="Tahoma" size="2">insuficiência respiratória, dispnéia e tosse.</font><br><font color="#808080" face="Tahoma" size="2">Corpo como um todo: dor torácica, fadiga.</font><br><font color="#808080" face="Tahoma" size="2">Sistema nervoso / Psiquiátricas: aumento nos sinais e sintomas de miastenia gravis, parestesia, insônia, pesadelos e perda</font><br><font color="#808080" face="Tahoma" size="2">de memória.</font><br><font color="#808080" face="Tahoma" size="2">Pele: alopecia, exacerbação de psoríase, erupção psoriásica.</font><br><font color="#808080" face="Tahoma" size="2">Hipersensibilidade: sinais e sintomas de reações alérgicas sistêmicas, incluindo angioedema, urticária, erupção cutânea</font><br><font color="#808080" face="Tahoma" size="2">localizada e generalizada.</font><br><font color="#808080" face="Tahoma" size="2">Imunológicas: lupus eritematoso sistêmico.</font><br><font color="#808080" face="Tahoma" size="2">Digestivas: náusea, diarréia e dispepsia.</font><br><font color="#808080" face="Tahoma" size="2">Òrgãos dos sentidos: diminuição da sensibilidade da córnea, distúrbios visuais incluindo alterações da refração (devidos à</font><br><font color="#808080" face="Tahoma" size="2">retirada de tratamento miótico em alguns casos), diplopia, ptose, separação da coróide após cirurgia filtrante e zumbidos.</font><br><font color="#808080" face="Tahoma" size="2">Urogenitais: diminuição da libido, doença de Peyronie.</font><br><font color="#808080" face="Tahoma" size="2">Eventos adversos de relação causal desconhecida com o timolol</font><br><font color="#808080" face="Tahoma" size="2">Foram relatadas as seguintes reações adversas, mas a relação causal com o tratamento com timolol não foi estabelecida:</font><br><font color="#808080" face="Tahoma" size="2">edema macular cistóide no afácico, congestão nasal, anorexia, efeitos sobre o sistema nervoso central (ex. alterações do</font><br><font color="#808080" face="Tahoma" size="2">comportamento incluindo confusão, alucinações, ansiedade, desorientação, nervosismo, sonolência e outros transtornos</font><br><font color="#808080" face="Tahoma" size="2">psíquicos), hipertensão, fibrose retroperitoneal e pseudopenfigóide.</font><br><font color="#808080" face="Tahoma" size="2">Exames laboratoriais clínicos: raramente alterações clinicamente importantes nos parâmetros laboratoriais padrão foram</font><br><font color="#808080" face="Tahoma" size="2">associadas à administração sistêmica do maleato de timolol. Ocorreram discretos aumentos no nitrogênio da uréia</font><br><font color="#808080" face="Tahoma" size="2">sangüínea, potássio sérico, ácido úrico sérico e triglicérides, e, discreta diminuição da hemoglobina e hematócrito e do HDLcolesterol,</font><br><font color="#808080" face="Tahoma" size="2">mas não foram progressivos ou associados com manifestações clínicas.</font><br><font color="#808080" face="Tahoma" size="2">Maleato de Timolol: Administração sistêmica: As reações adversas relatadas na experiência clínica com maleato de timolol</font><br><font color="#808080" face="Tahoma" size="2">oral podem ser consideradas como potenciais efeitos colaterais do maleato de timolol oftálmico.</font><br><font color="#808080" face="Tahoma" size="2">Eventos adversos graves relatados em pacientes pediátricos</font><br><font color="#808080" face="Tahoma" size="2">Foram relatados eventos adversos graves em associação com a administração de tartarato de brimonidina solução oftálmica</font><br><font color="#808080" face="Tahoma" size="2">0,2% em lactentes na faixa etária de 28 dias a 3 meses. Essas reações incluíram: bradicardia, hipotensão, hipotermia,</font><br><font color="#808080" face="Tahoma" size="2">hipotonia, apnéia, dispnéia, hipoventilação, cianose e letargia, resultando em hospitalização. Com a interrupção do tratamento</font><br><font color="#808080" face="Tahoma" size="2">com o tartarato de brimonidina 0,2% os lactentes se recuperaram sem seqüelas.</font><br><font color="#808080" face="Tahoma" size="2">ATENÇÃO: Este é um medicamento novo e, embora as pesquisas tenham indicado eficácia e segurança aceitáveis</font><br><font color="#808080" face="Tahoma" size="2">para comercialização, efeitos indesejáveis e não conhecidos podem ocorrer . Neste caso, informe seu médico.</font><br><font color="#808080" face="Tahoma" size="2">11. SUPERDOSE</font><br><font color="#808080" face="Tahoma" size="2">Não foram relatados casos de superdose com COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) solução oftálmica</font><br><font color="#808080" face="Tahoma" size="2">em humanos. Há relatos de superdose acidental com solução oftálmica de timolol resultando em efeitos sistêmicos</font><br><font color="#808080" face="Tahoma" size="2">semelhantes àqueles observados com agentes bloqueadores beta-adrenérgicos sistêmicos, tais como tontura, cefaléia,</font><br><font color="#808080" face="Tahoma" size="2">respiração curta, bradicardia, broncoespasmo e parada cardíaca. Um estudo de pacientes com insuficiência renal mostrou que</font><br><font color="#808080" face="Tahoma" size="2">o timolol não sofre diálise facilmente.</font><br><font color="#808080" face="Tahoma" size="2">O tratamento de superdose oral inclui medidas de suporte e tratamento sintomático, bem como manutenção das vias</font><br><font color="#808080" face="Tahoma" size="2">respiratórias livres. O esvaziamento gástrico deve ser considerado durante as primeiras poucas horas após ingestão de</font><br><font color="#808080" face="Tahoma" size="2">superdose.</font><br><font color="#808080" face="Tahoma" size="2">As medidas terapêuticas específicas para o tratamento de superdose de maleato de timolol são as seguintes: Lavagem</font><br><font color="#808080" face="Tahoma" size="2">gástrica: se for ingerido. Bradicardia sintomática: usar sulfato de atropina por via intravenosa, na dose de 0,25 a 2 mg para</font><br><font color="#808080" face="Tahoma" size="2">induzir bloqueio vagal. Se a taquicardia persistir, administrar, com cautela, cloridrato de isoproterenol por via intravenosa. Em</font><br><font color="#808080" face="Tahoma" size="2">casos refratários, o uso de marca-passo cardíaco pode ser considerado. Hipotensão: usar agente pressor simpatomimético,</font><br><font color="#808080" face="Tahoma" size="2">tais como dopamina, dobutamina ou levarterenol. Tem sido relatado que, em casos refratários, o uso do cloridrato de</font><br><font color="#808080" face="Tahoma" size="2">glucagon pode ser útil. Broncoespasmo: usar cloridrato de isoproterenol. Pode-se considerar tratamento adicional com</font><br><font color="#808080" face="Tahoma" size="2">aminofilina. Insuficiência cardíaca aguda: devem-se instituir imediatamente os tratamentos convencionais com digitálicos,</font><br><font color="#808080" face="Tahoma" size="2">diuréticos e oxigênio. Em casos refratários o uso de aminofilina intravenosa é sugerido. Este pode ser seguido, se necessário,</font><br><font color="#808080" face="Tahoma" size="2">por cloridrato de glucagon que tem sido considerado útil. Bloqueio cardíaco de segundo ou terceiro grau: usar cloridrato de</font><br><font color="#808080" face="Tahoma" size="2">isoproterenol ou marcapasso cardíaco transvenoso.</font><br><font color="#808080" face="Tahoma" size="2">12. ARMAZENAGEM</font><br><font color="#808080" face="Tahoma" size="2">O produto COMBIGAN® (tartarato de brimonidina 0,2% e timolol 0,5%) solução oftálmica deve ser mantido em temperatura</font><br><font color="#808080" face="Tahoma" size="2">ambiente (entre 15°C e 30°C) e protegido da luz.</font><br><font color="#808080" face="Tahoma" size="2">DIZERES LEGAIS</font><br><font color="#808080" face="Tahoma" size="2">Reg. ANVISA/MS - 1.0147.0162</font><br><font color="#808080" face="Tahoma" size="2">Farm. Resp.: Dra. Flávia Regina Pegorer</font><br><font color="#808080" face="Tahoma" size="2">CRF-SP nº 18.150</font><br><font color="#808080" face="Tahoma" size="2">VENDA SOB PRESCRIÇÃO MÉDICA</font><br><font color="#808080" face="Tahoma" size="2">Nº de lote e data de fabricação: vide cartucho.</font><br><font color="#808080" face="Tahoma" size="2">BIBLIOGRAFIA</font><br><font color="#808080" face="Tahoma" size="2">1. Day D. Sall K. Stewart W. A multicenter, investigator masked, randomized, parallel, active control study on brimonidina</font><br><font color="#808080" face="Tahoma" size="2">tartrate 0,2% /timolol 0,5% ophthalmic solution in patients with glaucoma or ocular hypertension. Study nº 190342-011T 1999.</font><br><font color="#808080" face="Tahoma" size="2">Data on file Allergan Inc.</font><br><font color="#808080" face="Tahoma" size="2">2. Talluri K. A Pharmacokinetic Report for Study 190342-016T entitled "A Single-Center, Randomized, Double-masked,</font><br><font color="#808080" face="Tahoma" size="2">Crossover Study to Evaluate the Safety and Pharmacokinetic Profile of Twice-Daily Administration of 0,2% Brimonidine</font><br><font color="#808080" face="Tahoma" size="2">Tartrate/0,5% Timolol fixed Combination Ophthalmic Solution Compared with Alphagan® (0,2% Brimonidina Tartrate) and</font><br><font color="#808080" face="Tahoma" size="2">Timoptic® (0,5% Timolol Maleate) Monotherapy Twice-Daily, in Normal, Healthy, Adult subjects for Seven Days." Study</font><br><font color="#808080" face="Tahoma" size="2">Report Nº PK-00-207. Dated February 2001. Data on File Allergan Inc.</font><br><font color="#808080" face="Tahoma" size="2">3. Whitcup SM. Lambert J. A multicenter double-masked, randomized, parallel study of the safety and efficacy of 0,2%</font><br><font color="#808080" face="Tahoma" size="2">brimonidina tartrate / 0,5% timolol combination ophthalmic solution twice-daily compared with 0,5% timolol twice-daily or</font><br><font color="#808080" face="Tahoma" size="2">Alphagan® three-times-daily for three months (plus 9-month, masked extension) in patients with glaucoma or ocular</font><br><font color="#808080" face="Tahoma" size="2">hypertension. Clinical Study Report 190342-012T, Phase 3. 3-month database lock date: 20 March 2001. Data on file Allergan</font><br><font color="#808080" face="Tahoma" size="2">Inc.</font><br><font color="#808080" face="Tahoma" size="2">4. Whitcup SM. Lambert J. A multicenter double-masked, randomized, parallel study of the safety and efficacy of 0,2%</font><br><font color="#808080" face="Tahoma" size="2">brimonidina tartrate / 0,5% timolol combination ophthalmic solution twice-daily compared with 0,5% timolol twice-daily or</font><br><font color="#808080" face="Tahoma" size="2">Alphagan® three-times-daily for three months (plus 9-month, masked extension) in patients with glaucoma or ocular</font><br><font color="#808080" face="Tahoma" size="2">hypertension. Clinical Study Report 190342-013T, Phase 3. 3-month database lock date: 18 april 2001. Data on file Allergan</font><br><font color="#808080" face="Tahoma" size="2">Inc.</font><br><font color="#808080" face="Tahoma" size="2">Qualidade e Tradição a Serviço da Oftalmologia</font><br><font color="#808080" face="Tahoma" size="2">Allergan Produtos Farmacêuticos LTDA</font><br><font color="#808080" face="Tahoma" size="2">Av. Guarulhos, 3.272 - CEP 07030-000 - Guarulhos - SP</font><br><font color="#808080" face="Tahoma" size="2">CNPJ 43.426.626/0009-24</font><br><font color="#808080" face="Tahoma" size="2">Indústria Brasileira</font><br><font color="#808080" face="Tahoma" size="2">® Marca Registrada</font></div>
                    </p>
                </div>
                
                <div class="tab-content video">
                    <p>
                        
                    </p>
                </div>
            </div>
            <div class="ch_clear" chaordic="middle"></div>
            
            <div class="ch_clear" chaordic="bottom"></div>
        </div>
    </div>
    <div class="zx_48A4A1065492484E8D54 zx_mediaslot">
       <script type="text/javascript">
           /*<![CDATA[*/
           window._zx = window._zx || [];
           window._zx.push({
               id: "48A4A1065492484E8D54"
           });
           (function (e) {
               var c = e.createElement("script");
               c.async = true;
               c.src = (e.location.protocol == "https:" ? "https:" : "http:") + "//static.zanox.com/scripts/zanox.js?utm_source=Zanox&utm_medium=Afiliados&utm_campaign=Desconto&acao=3&partner=576";
               var b = e.getElementsByTagName("script")[0];
               b.parentNode.insertBefore(c, b)
           }(document)); /*]]>*/
        </script>
        <script type="text/javascript">
            var images = window.chaordic_meta.product.images;
            var zx_identifier = window.chaordic_meta.product.id;
            var zx_name = window.chaordic_meta.product.name;
            var zx_price = window.chaordic_meta.product.price;
            var zx_url = window.location.host + window.chaordic_meta.product.url;
            var zx_photo = window.location.host + images["300x300"];
        </script>
        <script type="text/javascript">
            var IP;
            /*<![CDATA[*/
            function incrementValue() {
                var a = parseInt(document.getElementById("txt_QtdDP").value, 10);
                a = isNaN(a) ? 0 : a;
                a++;
                if (a == 21) {
                    a = 20
                }
                //if (a < 10) {
                //    a = ("0" + a)
                //}

                document.getElementById("txt_QtdDP").value = a
            }

            function DecrementValue() {
                var a = parseInt(document.getElementById("txt_QtdDP").value, 10);
                a = isNaN(a) ? 0 : a;
                a--;
                if (a == 0) {
                    a = 1
                }
                //if (a < 10) {
                //    a = ("0" + a)
                //}
                document.getElementById("txt_QtdDP").value = a
            }
            $("#txt_QtdDP").on("keyup blur", function (a) {
                $(this).val($(this).val().replace(/[^\d].+/, ""));
                if ((a.which < 48 || a.which > 57)) {
                    a.preventDefault()
                }


            });

            //$("#txt_QtdDP").on("keyup blur", function () {
            //    if ($("#txt_QtdDP").val() > 50) {
            //        $("#txt_QtdDP").val("0" + 1)
            //    }
            //    if ($("#txt_QtdDP").val() == "") {
            //        $("#txt_QtdDP").val("0" + 1)
            //    }
            //}); /*]]>*/




            $.get("https://ipinfo.io", function (response) {
                IP = response.ip;
            }, "jsonp");


            $("#cphConteudo_btComprarDP").click(function () {

                SalvarCRMProduto();
            });


            function SalvarCRMProduto() {

                $.ajax({
                    type: "POST",
                    url: "/DetalheProduto/Default.aspx/SalvarCrm",
                    data: "{id_produto:'" + $("#cphConteudo_hf_id_produto").val() + "',UF:'" + $("#cphConteudo_slCrmUF").val() + "',CRM:'" + $("#cphConteudo_txtCrm").val() + "',IP:'" + IP + "'}",
                    contentType: "application/json; charset=utf-8",
                    dataType: "json",
                    success: function (data) {
                        //if (data.d == "Salvo") {


                        //} else if (data.d == "Não Salvo") {

                        //}

                    },
                    error: function (data) {

                    }
                });

            }

        </script>
    </div>
    <style type="text/css">
		#lblProductName{
			text-transform:capitalize;
		}
	
        #cphConteudo_divSeloDermaclub {
            cursor: default;
        }

            #cphConteudo_divSeloDermaclub:hover {
                cursor: pointer;
            }
    </style>
    <script type="text/javascript">

     

    </script>

     <!-- SCRIPT MAPPER CLEARSALE -->
                                                                    <script>
                                                                        (function (a, b, c, d, e, f, g) {
                                                                            a['CsdmObject'] = e; a[e] = a[e] || function () {
                                                                                (a[e].q = a[e].q || []).push(arguments)
                                                                            }, a[e].l = 1 * new Date(); f = b.createElement(c),
                                                                                g = b.getElementsByTagName(c)[0]; f.async = 1; f.src = d; g.parentNode.insertBefore(f, g)
                                                                        })(window, document, 'script', '//device.clearsale.com.br/m/cs.js', 'csdm');
                                                                        csdm('app', '7cca55c77d');
                                                                    </script>
                                                <!--FIM SCRIPT MAPPER CLEARSALE -->


                <!-- conteudo -->
            </div>
        </div>
        <!-- FIM ESTRUTURA -->
        <!-- FOOTER -->
        <div class="pre-footer row">
            <div class="wrapper full">
                <div class="col newsletter">
                    <h5 class="news-title">Newsletter!</h5>
                    <p class="news-sub-title"><span>Cadastre-se</span></p>
                    <p class="text">Fique por dentro de todas as nossas promoções e descontos exclusivos.</p>
                    <input type="email" class="input-email" placeholder="Digite seu email" id="txtnewslettermaster" />
                    <a class="btn btn-acqua" onclick="AdicionarNewsLetter(1)">OK</a>
                    <p id="NewsLetterMaster" class="textNewsLetter"></p>
                </div>
                <div class="col cvs">
                    <p align="center">
                        <img class="img-cvs-health" src="https://www.onofre.com.br/assets/img/cvs-health-logo-grande.jpg" alt="CVS Health" />
                    </p>
                    <p class="text">Desde 2013, a Drogaria Onofre faz parte da maior empresa de saúde do mundo, CVS Health. Com mais de 7.500 drogarias distribuídas por todo o território americano, e 47 no Brasil. </p>
                    <a href="/Institucional/Default.aspx?InstId=230" class="btn btn-red" title="Saiba mais sobre a CVS Health">CLique aqui</a>
                </div>
                <div class="col lojas last">
                    <div class="info">
                        <h5>Nossas Lojas</h5>
                        <p class="text">A Drogaria Onofre possui 47 lojas em todo o território nacional e oferece mais de 15 horas de atendimento farmacêutico por dia.</p>
                        <a href="/nossaslojas/nossaslojas.aspx" class="btn btn-blue" title="Veja mais lojas">Clique aqui</a>
                    </div>
                    <img src="https://www.onofre.com.br/assets/img/banner-nossas-lojas.jpg" alt="Conheça nossas lojas" />
                </div>
            </div>
            <!-- /wrapper prefooter -->
        </div>
        <!-- /prefooter -->
        <footer class="page-footer">
                                        <div class="page-footer-top row">
                                            <div class="wrapper">
                                                <div class="row top-items">
                                                    
                                                            <div class="col4">
                                                                <h5 class="box-title">Sobre a Onofre</h5>
                                                                <ul class="links-list">
                                                                    
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=93' target='' class="list-link">
                                                                                    Quem Somos
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/nossaslojas/nossaslojas.aspx' target='' class="list-link">
                                                                                    Nossas Lojas
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.vagas.com.br/onofre' target='' class="list-link">
                                                                                    Trabalhe Conosco
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/nossaspoliticas' target='' class="list-link">
                                                                                    Nossas Políticas
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=207' target='' class="list-link">
                                                                                    Imprensa
                                                                                </a>
                                                                            </li>
                                                                        
                                                                </ul>
                                                            </div>
                                                        
                                                            <div class="col4">
                                                                <h5 class="box-title">Serviços</h5>
                                                                <ul class="links-list">
                                                                    
                                                                            <li class="list-item">
                                                                                <a href='https://portal.anvisa.gov.br/wps/portal/anvisa/informetecnico/!ut/p/c5/04_SB8K8xLLM9MSSzPy8xBz9CP0os3hnd0cPE3MfAwMDMydnA093Uz8z00B_A3dTU6B8JE55A38jArrDQfbh1w-SN8ABHA30_Tzyc1P1I_WjzBGmuBtamBt4WribujmFOhsbhBnqR-akpicmV-oX5EYYZJmEKgIAztfaUw!!/dl3/d3/L2d' target='_blank' class="list-link">
                                                                                    Alertas e Informes Anvisa
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.cff.org.br/' target='_blank' class="list-link">
                                                                                    Conselho Federal de Farmácia
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://portal.cfm.org.br/' target='_blank' class="list-link">
                                                                                    Conselho Federal de Medicina
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=25' target='' class="list-link">
                                                                                    Aplicativo Onofre para iPhone e Android
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='/mapa-site' target='' class="list-link">
                                                                                    Mapa do Site
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://portalsaude.saude.gov.br/index.php/o-ministerio/principal/secretarias/sctie/farmacia-popular' target='_blank' class="list-link">
                                                                                    Farmácia Popular
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/entregaRapida/' target='' class="list-link">
                                                                                    Entrega Rápida
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=275' target='' class="list-link">
                                                                                    Monte sua farmacinha
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=28' target='' class="list-link">
                                                                                    Confira condições de frete
                                                                                </a>
                                                                            </li>
                                                                        
                                                                </ul>
                                                            </div>
                                                        
                                                            <div class="col4">
                                                                <h5 class="box-title">Relacionamento</h5>
                                                                <ul class="links-list">
                                                                    
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/CentralCliente/Default.aspx' target='' class="list-link">
                                                                                    Central do Cliente
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/FaleConosco/' target='' class="list-link">
                                                                                    Fale Conosco
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/centralajuda/centralajuda.aspx' target='' class="list-link">
                                                                                    Central de Ajuda
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/falefarmaceutico/' target='' class="list-link">
                                                                                    Fale com o Farmacêutico
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://blog.onofre.com.br/' target='' class="list-link">
                                                                                    Blog da Onofre
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://www.onofre.com.br/Institucional/Default.aspx?InstId=97' target='' class="list-link">
                                                                                    Troca e Devolução
                                                                                </a>
                                                                            </li>
                                                                        
                                                                            <li class="list-item">
                                                                                <a href='https://chat_online' target='' class="list-link">
                                                                                    Chat Online
                                                                                </a>
                                                                            </li>
                                                                        
                                                                </ul>
                                                            </div>
                                                        
                                                    <div class="col4 apps last">
                                                        <h5 class="box-title">Aplicativo Onofre</h5>
                                                        <p>Baixe os nossos aplicativos e tenha nossas ofertas na palma da mão</p> <span>Baixar Apps</span> <a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=25" target="_blank" class="app-link apple">Apple</a> <a href="https://www.onofre.com.br/Institucional/Default.aspx?InstId=25" target="_blank" class="app-link android">Android</a> </div>
                                                </div>
                                                <div class="row bottom-items">
                                                    <div class="col8">
                                                        <h6>Compre pelo telefone</h6>
                                                        <div class="tel">
                                                            <p>4007-2526</p>
                                                            <span>(Custo de uma ligação local)</span><br />
                                                            <span>Horário das 8h às 21h, de segunda a sábado</span>
                                                        </div>                                                        
                                                        <div class="tel" style="float:right" >
                                                            <p>0800-609-3030</p> <span>Demais localidades</span> 
                                                        </div>
                                                    
                                                        <div class="col8" style="margin: 10px 0px 0px 0px"> Caro cliente, a Drogaria Onofre informa que, temporariamente, os pedidos realizados no site após às 21h de sábado serão processados na segunda-feira, a partir das 8h. Desta forma, ressaltamos que o prazo de entrega da sua compra
                                                            <br> será calculado a partir desta data. </div>
                                                    </div>
                                                    <div class="col5 social">
                                                        <h6>Acompanhe a Onofre</h6>
                                                        <ul class="social-links">
                                                            <li class="social-item"><a class="social-link facebook" href="https://www.facebook.com/DrogariaOnofreOficial" class="social-link facebook" target="_blank" title="Facebook">Facebook</a></li>
                                                            
                                                                <li class="social-item"><a href="https://www.instagram.com/drogariaonofre/" class="social-link instagram" target="_blank" title="Instagram">Instagram</a></li>
                                                                <li class="social-item">
                                                                    <a href="https://blogonofre.wordpress.com" target="_blank"> <img src="https://www.onofre.com.br/assets/img/be-onofre-logo.jpg" alt="Be onofre" /></a>
                                                                </li>
                                                        </ul>
                                                    </div>
                                                </div>
                                            </div>
                                            <!-- /wrapper page-footer-top -->
                                        </div>
                                        <!-- /page-footer-->
                                        <div class="page-footer-bottom row">
                                            <div class="wrapper">
                                                <div class="col8">
                                                    <p class="title-box">Formas de pagamento</p> <img class="img-formas-pagamento-master" src="https://www.onofre.com.br/assets/img/formas-de-pagamento.jpg" alt="Visa, MasterCard, Amex, Diners, Hipercard, Aura e Boleto bancário" /> </div>
                                                <div class="col5 seguranca">
                                                    <p class="title-box">Segurança</p>
                                                    <ul class="selos">
                                                        <li>
                                                            <a id="seloEbit" href="https://www.ebit.com.br/onofre-em-casa" target="_blank" onclick="redir(this.href)" style="background-image: url(&quot;https://a248.e.akamai.net/f/248/52872/0s/img.ebit.com.br/ebitBR/selo/img_973.png&quot;); width: 89px; height: 95px; display: block; overflow: hidden; position: relative; float: left" title="Avaliado pelos consumidores"></a>
                                                        </li>
                                                        <li>
                                                            <!-- COMODO -->
                                                            <script language="javascript" type="text/javascript">
                                                                /*<![CDATA[*/
                                                                var tl_loc0 = (window.location.protocol == "https:") ? "https://secure.comodo.net/trustlogo/javascript/trustlogo.js" : "https://www.trustlogo.com/trustlogo/javascript/trustlogo.js";
                                                                document.writeln('<script language="JavaScript" src="' + tl_loc0 + '" type="text/javascript"><\/script>'); /*]]>*/
                                                            </script>
                                                            <!-- COMODO -->
                                                            <script language="JavaScript" type="text/javascript">
                                                                TrustLogo("https://www.onofre.com.br/img/Rodape/comodo.png", "SC5", "none");
                                                            </script>
                                                        </li>
                                                    </ul>
                                                </div>
                                            </div>
                                            <!-- /wrapper page-footer -->
                                        </div>
                                        <!-- /page-footer-bottom -->
                                        <div class="row">
                                            <div class="wrapper"> <address class="col16"> <span id="lblDescriptionAddress"><p align="center"><span style="color: #888888;">Drogaria Onofre Ltda | CNPJ 61.549.259/0013-14 | IE 115.276.053.114 | Av. da Liberdade, 902 Complemento 904 - Liberdade | São Paulo (SP) | Horário de funcionamento: Segunda a Domingo 07:00 às 22:00 | CEP: 01502-001 | Telefone 4007-2526</span><br /><span style="color: #888888;">Farmacêutico Responsável: Dra. Thais Briotto de Andrade dos Santos | CRF - SP: 53.912 | AFE: 7.46544-5 | CMVS: 35503080147700867012</span></p>
<p align="center"><span style="color: #888888; font-family: tahoma, arial, helvetica, sans-serif; font-size: x-small;">As informações contidas neste site não devem ser usadas para automedicação e não substituem, em hipótese alguma, as orientações dadas pelo profissional da área médica. Somente o médico está apto a diagnosticar qualquer problema de saúde e prescrever o tratamento adequado. Ao persistirem os sintomas, o médico deverá ser consultado. Os preços e promoções divulgados no site são válidos apenas para compras feitas pela Internet e podem variar conforme região de entrega. Em caso de divergência, o preço válido é o do carrinho de compras. Imagens meramente ilustrativas. Este site é melhor visualizado na configuração 1024x768.</span><br /><span style="color: #888888; font-family: tahoma, arial, helvetica, sans-serif; font-size: x-small;">Copyright © 1999 - 2016 Onofre em Casa. Todos os direitos reservados.</span><br /><span style="color: #888888; font-family: tahoma, arial, helvetica, sans-serif; font-size: x-small;">*Desconto não válido para todos os produtos dessa página</span></p></span> </address>
                                                 </div>
                                        </div>
                                        <!-- /wrapper copyright -->
                                        </div>
                                        <div id="armored_website">
                                            <param id="aw_preload" value="true" /> </div>
                                        <script type="text/javascript" src="//selo.siteblindado.com/aw.js"></script>
                                        <!-- /copyright -->
                                    </footer>
        <!-- /page-footer -->
        <!-- FIM FOOTER -->
        
    </form>
    <!-- Script Chat online-->
    <script>
        var chat_online = $("a[href='https://chat_online']").removeAttr("href");
        chat_online.click(function (event) { window.open("https://onofre.custhelp.com/app/chat/chat_launch", "Chat Online Drogaria Onofre", "top=80,left=900,width=475,height=715"); });
    </script>
    <!--END chat online -->


    <!-- ------------------------------------------------------------------------------------------------------------- -->
    <!-- -------------------------------------------------- SCRIPTS -------------------------------------------------- -->
    <!-- ------------------------------------------------------------------------------------------------------------- -->
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//www.googletagmanager.com/ns.html?id=GTM-5SFH26" height="0" width="0" style="display: none; visibility: hidden"></iframe>
    </noscript>
    <script>
        /*<![CDATA[*/
        (function (f, d, l, i, n) {
            f[i] = f[i] || [];
            f[i].push({
                "gtm.start": new Date().getTime(),
                event: "gtm.js"
            });
            var j = d.getElementsByTagName(l)[0],
                o = d.createElement(l),
                p = i != "dataLayer" ? "&l=" + i : "";
            o.async = true;
            o.src = "//www.googletagmanager.com/gtm.js?id=" + n + p;
            j.parentNode.insertBefore(o, j)
        })(window, document, "script", "dataLayer", "GTM-5SFH26"); /*]]>*/
    </script>
    <!-- End Google Tag Manager -->
 


      <script>

          var AbertoLoginBox = false;


          function ExibirPopupLogin(a, b, c) {
              $.colorbox({
                  href: a,
                  open: !0,
                  iframe: !0,
                  scrolling: !0,
                  opacity: .5,
                  overlayClose: false,
                  transition: "fade",
                  height: c,
                  width: b,
                  fixed: !0,
                  closeButton: true,
                  className: "colorbox_login",

              });

              AbertoLoginBox = true;

              $(document).bind('cbox_complete', function () {

                  $("#cboxClose").hide();
                  $("#cboxClose").html("X");
                  $("#cboxClose").attr("class", "fecharBoxLogin");
                  $("#cboxClose").css("text-indent", "0px")
                  $("#cboxClose").css("text-indent", "0px")
                  $("#cboxClose").css("border", "2px solid rgb(216, 216, 216)")
                  $("#cboxClose").css("background-color", "white")
                  $("#cboxClose").css("color", "rgb(216, 216, 216)")
                  $("#cboxClose").css("top", "2px")
                  $("#cboxClose").css("right", "2px")                 
                  $("#cboxClose").show();

                  $("#cboxClose").click(function () {

                      $.colorbox.close();

                  });

                 
              }); 

          }

      </script>
      <script type="text/javascript">

        setTimeout(function () {
            var url = "../../../Jss/Colorbox/jquery.colorbox-min.js";
            $.getScript(url, function () {
                console.log("jquery.colorbox-min Carregado!");
            });
        },1300);

    </script>
    
    <!-- ------------------------------------------------------------------------------------------------------------- -->
    <!-- -------------------------------------------------- SCRIPTS -------------------------------------------------- -->
    <!-- ------------------------------------------------------------------------------------------------------------- -->
     
</body>
<link href="assets/css/chaordic.css" rel="stylesheet" />


</html>
